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Abstract
The HIV/AIDS pandemic has been a torment to the African developmental agenda,
especially the Southern African Development Countries (SADC), for the past two
decades. The disease and condition tends to affect the productive age groups. Chil-
dren have also not been spared from the severe effects associated with the disease. The
advent of antiretroviral treatment (ART) has brought a great relief to governments
and patients in these regions. More people living with HIV/AIDS have experienced
a boost in their survival prospects and hence their contribution to national develop-
mental projects.
Survival analysis methods are usually used in biostatistics, epidemiological modelling
and clinical research to model time to event data. The most interesting aspect of this
analysis comes when survival models are used to determine risk factors for the sur-
vival of patients undergoing some treatment or living with a certain disease condition.
The purpose of this thesis was to determine prognostic risk factors for patients’ sur-
vival whilst on ART. The study sought to highlight the risk factors that impact the
survival time negatively at different survival time points. The study utilized a sam-
ple of paediatric and adult datasets from Namibia and Zimbabwe respectively. The
paediatric dataset from Katutura hospital (Namibia) comprised of the adolescents
and children on ART, whilst the adult dataset from Bulawayo hospital (Zimbabwe)
comprised of those patients on ART in the 15 years and above age categories. All
datasets used in this thesis were based on retrospective cohorts followed for some
x
 
 
 
 
xi
period of time. Different methods to reduce errors in parameter estimation were em-
ployed to the datasets. The proportional hazards, Bayesian proportional hazards and
the censored quantile regression models were utilized in this study.
The results from the proportional hazards model show that most of the variables
considered were not significant overall. The Bayesian proportional hazards model
shows us that all the considered factors had different risk profiles at the different
quartiles of the survival times. This highlights that by using the proportional haz-
ards models, we only get a fixed constant effect of the risk factors, yet in reality,
the effect of risk factors differs at different survival time points. This picture was
strongly highlighted by the censored quantile regression model which indicated that
some variables were significant in the early periods of initiation whilst they did not
significantly affect survival time at any other points in the survival time distribution.
The censored quantile regression models clearly demonstrate that there are significant
insights gained on the dynamics of how different prognostic risk factors affect patient
survival time across the survival time distribution compared to when we use propor-
tional hazards and Bayesian propotional hazards models. However, the advantages
of using the proportional hazards framework, due to the estimation of hazard rates
as well as it’s application in the competing risk framework are still unassailable. The
hazard rate estimation under the censored quantile regression framework is an area
that is still under development and the computational aspects are yet to be incorpo-
rated into the mainstream statistical softwares.
This study concludes that, with the current literature and computational support,
using both model frameworks to ascertain the dynamic effects of different prognostic
risk factors for survival in people living with HIV/AIDS and on ART would give the
researchers more insights. These insights will then help public health policy makers
to draft relevant targeted policies aimed at improving these patients’ survival time
on treatment.
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Chapter 1
General introduction
Survival modelling and analysis methods are generally used in clinical, biostatistics
and epidemiology research to model time until event data. Survival analysis refers
to statistical procedures designed to take into account the amount of time an experi-
mental unit contributes to a study period, that is, the time between entry into study
and occurrence of event of interest (Nakhaee & Law, 2011).
Survival analysis entails methods that measure the risk of death or progression of
a disease and provide predictions that can help clinicians to estimate trends in the
patient outcomes. These methods also allow health planners to predict the Hu-
man Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome (HIV/AIDS)
burden on the health system and to allocate health services resources appropriately
(Nakhaee & Law, 2011). Health care planning relies on a good understanding of
disease prevalence, which requires an accurate knowledge of survival patterns. Mon-
itoring the length of survival after diagnosis is, therefore, an important component
of the surveillance of HIV/AIDS as it provides the basis for evaluating individual
prognostic factors (Assefa & Wencheko, 2012). The survival of HIV/AIDS patients
1
 
 
 
 
2depends on a variety of factors including but not limited to the individual patient’s
demographic factors, serological baseline factors and presence of co-morbidities.
The most widely used survival modelling and analysis techniques include the Cox’s
proportional hazards models and the accelerated failure time (AFT) models. In the
last two to three decades, quantile regression (QR) models as introduced by Koenker
and Basset (Koenker & Bassett Jr, 1978) have become an alternative technique to
describe and contextualize the distribution of a response variable given a set of ex-
planatory variables. Quantile regression models are very flexible in assessing covariate
effects on event times, thereby attracting huge interest in their application to survival
modelling.
Survival data is commonly skewed and the marginal distribution of response vari-
able is characterised by marked skewness. Quantile regression methods are robust in
characterising and exploring the distribution of skewed data (for example duration
or survival data) hence are emerging as popular techniques in survival modelling.
According to Fitzenberger and Wilke (2005) quantile regressions are used to model
changes of quantiles of the conditional distribution of the survival time in response
to changes in the explanatory variables (Fitzenberger & Wilke, 2005).
Whilst in conventional regressions (in this case, the Cox’s proportional hazards mod-
els), estimators show that the survival times or failure times recognise the presence of
some risk factors, quantile regression analysis adds a new dimension to the literature,
suggesting that the influence of the risk factor on the survival times varies across the
 
 
 
 
3survival time distribution. For patients with higher duration (survival) times, the
survival function will barely recognise some risk factors whilst for patients with the
lowest survival times; their survivor function is particularly sensitive to the presence
of some risk factors.
Thus, quantile regression techniques can help us get a more complete picture of the
underlying relationships between risk factors and the survival time. Censored quan-
tile regression (CQR) like proportional hazards models addresses the issue of right
censoring of the response variable, which is common in survival analysis.
By modelling the distribution of the survival time in a flexible semi-parametric way,
quantile regression does not impose modelling assumptions that may not be empir-
ically valid like in the case of the proportional hazards assumption for the Cox’s
proportional hazards regression models. Censored quantile regrssion models are more
flexible than the AFT models or the Cox’s proportional hazard model because they
do not restrict the variation of estimated coefficients over the quantiles (Fitzenberger
& Wilke, 2005).
1.1 The conceptual framework and objectives of
the study
Long-term sustainable treatment is one choice for people living with HIV/AIDS. Not
only can medications slow the progression of the infection, but they can also markedly
suppress the virus, thereby restoring the body’s immune function and permitting
many HIV-infected individuals to lead a normal life. People living with HIV/AIDS
 
 
 
 
4take a number of medications to sustain their survival, that is, to improve their
chances of better and longer survival.
Even though HIV/AIDS drugs have become cheaper and more available because of
a variety of government and private programmes, millions of others still do not have
access to the drugs. The World Health Organisation, WHO, (WHO, 2007) recom-
mends that in resource-limited settings like Zimbabwe, Namibia and other African
countries, HIV infected adolescents and adults should start antiretroviral treatment
(ART) when the following conditions are met: WHO clinical stage 4 regardless of
Cluster of Differentiation 4 (CD4) count, stage 3 disease with consideration of CD4
count below 350/mm3 in assisting decision making, stages 1 or 2 diseases with CD4
cell count below 200/mm3. In some settings where the CD4 count is not available,
the total lymphocyte count (TLC) can be used, and treatment is recommended for
WHO stages 3 or 4 (clinical AIDS) irrespective of the TLC, and stage 2 with TLC
not exceeding 1200/mm3.
With proper and timely use of antiretroviral therapy (ARVs) and good health care
support for people living with HIV/AIDS, it has been noted worldwide that the
survival time can be improved. The presence of opportunistic infections has how-
ever impacted negatively on this prospect. Some of the most lethargic opportunistic
illnesses which can drastically reduce HIV/AIDS patients’ survival time include Tu-
berculosis (TB), Pneumonia, and Hepatitis. Of these opportunistic illnesses, TB has
been proven to be the most deadly when it combines with HIV/AIDS (Mezzabotta,
2008; Ngwerume, 2008).
 
 
 
 
5A number of medical studies on the epidemiology of HIV/AIDS and co-morbidities
within the region have appealed to diverse descriptive and analytic statistical meth-
ods. The odds ratios (ORs) and relative risks (RRs) are commonly used to describe
and ascertain association between health outcomes and different risk factors. The
proportional hazards models (PHM) on the other hand are used to identify and ex-
plain the relationship between survival time and the different risk factors such as
opportunistic diseases status, HIV status, CD4 count, WHO HIV/AIDS stages, sex,
age, and alcohol taking (Mutasa-Apollo et al., 2014; Ngwerume, 2008; Zachariah et
al., 2006). All these methods are important as they give a quick picture and appre-
ciation of the dangers posed by the different associations in the variables.
However, the survival times for HIV/AIDS patients vary according to a number of
factors including socio-demographic factors, CD4 cell count, HIV viral load and some
AIDS defining illnesses. Therefore these covariates need to be tested in a censored
quantile regression model in order to allow prediction of these variables’ effects on
the time to the event of interest, that is death, from ART initiation.
Survival analysis thus represents a more dynamic situation which is not easily cap-
tured by commonly used methods like the proportional hazards ratios which only
reveal a static situation. For example, these methods can only indicate that a partic-
ular variable is a risk factor but they do not highlight at what point of the patient’s
survival time is the variable a significant risk factor. Thus there is an urgent need to
 
 
 
 
6apply censored quantile regression (CQR) models in conjunction with Cox’s propor-
tional hazards models in the analysis of HIV/AIDS patients’ survival times in order to
gain more insight into the effect of the different prognostic factors at different points
of the patients’ survival times. In addition, the information derived from the CQR
models will also be of significant use in the clinical area with regards to how patients
with AIDS defining illnesses and HIV/AIDS can best be managed to improve their
survival times.
This study sought to model new survival data from Namibia and Zimbabwe for
HIV/AIDS patients who are taking antiretroviral drugs using the Cox’s proportional
hazards, Bayesian proportional hazards and censored quantile regression models. The
study also did a comparative analysis of the inferential power associated with each of
the three modelling techniques.
1.2 Aim
The main aim of this study was to model and analyze the survival time distribution
for patients on HIV antiretroviral treatment in the presence of serological and clinical
risk factors, opportunistic diseases, and some demographic risk factors using different
survival modelling techniques.
1.3 Research objectives
The specific objectives for this research study were to:
1. Determine the risk factors for the survival of HIV/AIDS patients on antiretro-
viral treatment using the Cox’s proportional hazards model.
 
 
 
 
72. Determine the risk factors for the survival of HIV/AIDS patients on antiretro-
viral treatment using the Bayesian proportional hazards model.
3. Identify risk factors for the survival of HIV/AIDS patients on antiretroviral
treatment using the censored quantile regression model. Compare the result to
that from the Bayesian proportional hazards model.
4. Compare the effects of the different covariates across different quantiles of the
survival time distribution based on censored quantile regression and Cox’s pro-
portional hazards models.
5. Characterize the risk factors that affect HIV/AIDS patients’ survival in the
shorter to medium survival times.
1.4 Significance of the study
This study can give health researchers, biostatisticians and epidemiologists a better
picture of the alternative methods that can be used in duration (survival) data anal-
ysis. These methods can either be used by themselves or as complementary tools to
gain more insight into the risk factor dynamics at any given point of the patients’
survival time.
1.5 Thesis layout
The general structure of this thesis is divided into different sections as follows. The
first chapter deals with the general introduction to the study and also lays out the
different objectives to be met in this research study. The second chapter is devoted to
reviewing the literature that underlies the different survival modelling procedures that
 
 
 
 
8are to be employed in this study. The third chapter deals with the data selection and
methodologies applied. This chapter gives an explanation of the datasets used in this
study and provide details regarding the statistical methods utilized. The fourth chap-
ter presents an analysis and modelling of the paediatric dataset to determine survival
prognostic risk factors. The Cox’s proportional hazards models are implemented in
this chapter and risk factors are determined and discussed. The fifth chapter presents
the analysis and modelling of the paediatric dataset using the Bayesian proportional
hazards models and the censored quantile regression models. The inferential power
of these models are then discussed and compared. Chapters four, five and seven are
made up of submitted/published articles in accredited journals. Chapter six fits the
Cox’s proportional hazards model and the censored quantile regression models and
then compares and discusses the strengths and weaknesses of each of the models.
The seventh chapter implements the censored quantile regression on the adult ART
patients’ survival time to determine factors that influence the outcome of death in the
early periods (first year) of starting on ART. Chapter eight discusses and concludes
on the findings of the study and provides the recommendations.
 
 
 
 
Chapter 2
Literature review
In this chapter a concise review of the literature that underlies the methodologies
that were implemented in this study is covered. Literature is reviewed that surrounds
the concept of survival data analysis in relation to the HIV/AIDS pandemic. Brief
backgrounds to the history of the disease in each of the countries to be part of this
study are also reviewed.
2.1 HIV/AIDS epidemic in Zimbabwe
The first case of HIV/AIDS in Zimbabwe was initially reported in 1985. From that
moment, an increasing number of patients were observed to present with different ill-
nesses suggestive of HIV infection. In the years that followed, HIV/AIDS prevalence
increased from 2% in 1985 to 8.8% in 1995 (Kerina, Babill, & Muller, 2013) among
blood donors. A routine sentinel surveillance of pregnant women attending anti-natal
care clinics (ANC) commenced in 1990. Results from the first surveillance indicated
that the prevalence exceeded 10% among pregnant women. By the year 2000, preva-
lence among these women was around 32% but this reduced to about 16% by 2011
9
 
 
 
 
10
(Mbizvo et al., 1996; Gonese et al., 2010; Kerina et al., 2013). Surveillance data from
ANCs, for example, has over the years been used to provide estimates of HIV/AIDS
prevalence rates for adult populations. The national estimate for HIV/AIDS preva-
lence amongst adults, that is, 15 years and older, is currently (2014 estimate) esti-
mated at around 14.7%, down from around 21% in 2005 (Mundi, 2015).
Anti-retroviral therapy (ART) has substantially reduced HIV/AIDS related morbid-
ity and mortality worldwide. A growing body of empirical evidence and mathemat-
ical modelling suggests that expanded ART use may also prevent population-level
transmissions of HIV virus (Novitsky & Essex, 2012). An estimated one million six
hundred (1,600,000) people are living with HIV/AIDS in Zimbabwe, of which one
hundred and fifty thousand (150,000) are estimated to be children aged from birth
to 14 years (UNAIDS, 2014). Access to antiretroviral therapy (ART) in Zimbabwe
has been anything but easy. According to the MoHCW (2013), the number of people
living with HIV/AIDS disease in 2012 was estimated to be 1.3 million, whilst those
in need of ART was estimated to be 621,673 adults and 108,263 children (MoHCW,
2013).
Between 2007 and 2009 Zimbabwe suffered a severe socioeconomic crisis as a result
of extreme economic recession and hyperinflation. These conditions coupled with
drought significantly affected ART patients in particular as well as the general popu-
lation at large. The health system was seriously affected with major health facilities
experiencing shortages of essential medical supplies and health workers (Meldrum,
2008; Mutasa-Apollo et al., 2014).
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The National Opportunistic Infection/Antiretroviral Therapy (OI/ART) programme
in Zimbabwe was established in April 2004. From 2008 (Mutasa-Apollo et al., 2014),
both ART initiation and follow-up services have been decentralised to most of the
lower level health facilities. The rapid expansion of ART programmes in settings
with weak health systems is associated with high mortality and loss of patients to
follow-up (Nachega, Mills, & Schechter, 2010). A recent study by Mutasa-Apollo and
co-researchers on attrition in Zimbabwe for patients on ART indicated that gender,
body weight, WHO stage IV and level of health care were significant risk factors of at-
trition (including mortality) for patients on anti-retroviral treatment (Mutasa-Apollo
et al., 2014).
2.2 HIV/AIDS epidemic in Namibia
The government of the republic of Namibia started monitoring HIV/AIDS prevalence
since 1992 through the sentinel surveillance of pregnant women at selected antenatal
clinics throughout the country. In 1992 prevalence amongst this population group
was around 4.2% rising to its peak of 22% in 2002 (MoHSS, 2013).
Over the past two decades the HIV/AIDS pandemic in Namibia has negatively im-
pacted on health and development indicators, and remains a major challenge for the
next generations. Regardless of the decline in new HIV infections (incidence rates),
HIV prevalence in the country has stabilised at a high level and continues to bur-
den the health care system, fueling new infections and posing serious developmental
problems. The epidemic impacts both directly and indirectly on the well being of the
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vast majority of the population, the performance of the formal and informal sectors
of the economy, the capacity of public and private sectors to provide services, and the
attainment of the MDGs (Millennium Development Goals)(MoHSS-UNAIDS, 2011).
Namibia experiences a generalised HIV epidemic with an estimated 260,000 HIV in-
fected adults and children which represents an estimated prevalence of 13.1% (UNAIDS,
2014). However, deaths due to HIV/AIDS reduced from 6310 in 2010 to 5100 in 2014
(UNAIDS, 2014).
Given the impact of HIV/AIDS disease on it’s developmental prospects, the Namibian
government made significant deliberate efforts on improving the care and treatment
of HIV/AIDS. Providing universal access to HIV prevention, treatment, care and
support services has been a development priority for the past ten to fifteen years.
ART services have been scaled up rapidly in Namibia, with highly successful results.
More than 75,000 people were on ART in March 2007 (MoHSS-UNAIDS, 2011), and
nearly 50,000 people were on pre-ART in the same year. This roll-out of ART has
achieved large reductions in morbidity and mortality among people living with HIV
and AIDS.
2.3 Introduction to survival analysis and modelling
In order to understand the concepts that are core in this research, the next section
introduce and define the key terms used in this thesis.
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2.3.1 Survival analysis
Survival analysis is defined as a branch of statistics that involves the modelling of time
to event data. Some of the common areas of application includes biostatistics and
epidemiology, where the focus is on observing time to death or some health-related
event. Survival analysis explores and models time to event data focusing on the dis-
tribution of the survival times. The most profound survival analysis and modelling
examines the relationship between survival times and one or more predictors, usually
termed covariates in survival analysis literature (Fox, 2008).
The standard approaches to survival analysis and modelling are probabilistic (stochas-
tic). The assumption is that the times at which events occur are generated by a
random process. This implies that T, the event time, for some particular individual
is a random variable having a probability distribution (Allison, 2010).
2.3.2 Censoring
Censoring is the most common phenomenon that is associated with survival data.
This occurs when we fail to observe the end point of an event of interest. There are
four types of censoring. These are: right censoring, left censoring, interval censoring
and informative censoring.
1. Right censoring
Right censoring occurs when we only observe that a spell has survived until a
certain time (duration) (e.g. when the period of observation ends) but we do
not know exactly when it ended.
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2. Left censoring
Left censoring occurs when spells observed in the data started before the be-
ginning of the period of observation. Spells which started at the same time
and which finished before the beginning of the period of observation are not
observed.
3. Interval censoring
Interval censoring occurs when a spell is known to have occurred within some
time interval.
4. Informative censoring
Informative censoring occurs when a patient is withdrawn from the study for
other reasons.
In this study, considerations were made for the case of right censoring only because
it is supported in all the model frameworks that were used in this study.
2.3.3 Survival models
Survival modelling is concerned with models for data that have three main charac-
teristics which are:
1. The dependent variable or response is the waiting time until the occurrence of
a well defined event.
2. Observations are censored, in the sense that for some units the event of interest
has not occurred at the time the data are analysed.
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3. There are predictors or explanatory variables whose effect on the waiting time
we wish to assess or control.
2.3.4 Quantile regression
Quantile regression is a biostatistics, econometric and biometric tool in which a spec-
ified quantile (or percentile) of the conditional distribution of the response variable
is regressed on subject characteristics. Thus, while a regression coefficient from a
conventional ordinary least squares (OLS) regression model describes how the mean
response changes with a one-unit change in the predictor variable, a regression coef-
ficient from the quantile regression model describes how the specified quantile of the
response changes with a one-unit change in the predictor variable. This technique is
finding its application in survival data analysis due to the skewed nature of the data
involved. SAS implements this technique in it’s ”quantlife” procedure whilst in R it
is supported in the ”quantreg” package.
2.3.5 Cox’s proportional hazards models
Cox’s proportional hazards models are the most commonly used modelling frame-
works for examining the relationship of the survival time distribution to the different
potential risk factors. Most commonly, this examination entails the specification of
a linear-like model for the log-hazard (Fox, 2008). This is a semi-parametric survival
model with the assumption of proportionality in the hazards. The details of this
modelling framework are discussed in the next section.
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2.4 Proportional hazards modelling (PHM)
Cox’s Proportional Hazards Modelling (PHM) is the basic modelling technique used
in exploring the relationship between the survival experience of a patient and potential
risk factors in survival data analysis. This model was proposed by Cox (Cox, 1972;
Cox & Oakes, 1984) and it has come to be known as the Cox proportional hazards
regression models. Although the model is based on the assumption of proportional
hazards, no particular form of probability distribution is assumed for the survival
times. The model is thus semi-parametric in nature.
2.4.1 Model specification for the PHM
Most commonly, this examination of the relationship between survival time and ex-
planatory variables (risk factors) entails the specification of a linear-like model for the
log hazard. For example, a parametric model based on the exponential distribution
may be written as:
log hi(t) = α + β1xi1 + β2xi2 + · · ·+ βpxip, (2.4.1)
or equivalently:
hi(t) = exp(α + β1xi1 + β2xi2 + · · ·+ βpxip). (2.4.2)
that is, as a linear model for the log-hazard or as a multiplicative model for the hazard.
Here i is a subscript for observation, and the x’s are the covariates. The constant α in
this model represents a kind of log-baseline hazard, since log hi(t) = α [or hi(t) = e
α]
when all the x’s are zero.
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The Cox proportional hazards model, in contrast, leaves the baseline hazard func-
tion α(t) = log h0(t) unspecified. That is:
log hi(t) = α(t) + β1xi1 + β2xi2 + · · ·+ βpxip, (2.4.3)
or equivalently:
hi(t) = h0(t)exp(β1xi1 + β2xi2 + · · ·+ βpxip). (2.4.4)
This model is semi-parametric as the baseline hazard can take any form, and the
covariates enter the model linearly (Fox, 2008).
This same model can be represented as:
hi(t|xi) = h0(t)exp(X ′iβ). (2.4.5)
In this model, h0(t) is the baseline hazard function that describes the risk for indi-
viduals with xi = 0, who serve as the reference cell or pivot, and exp(X
′
iβ) is the
relative risk, a proportionate increase or reduction in risk, associated with the set
of characteristics X
′
i . The increase or reduction in risk is the same at all durations
t (Rodrıguez, 2010). This model assumes that the underlying hazard rate (rather
than the survival time) is a function of the independent variables (covariates); no
assumptions are made about the nature or shape of the hazard function.
Consider a case whereby we are dealing with two groups, that is, say patients are
randomised to receive either a standard treatment or a new treatment, and let hS(t)
and hN(t) be the hazards of death at time t for patients on the standard treatment
and new treatment respectively, according to a simple model for the survival times of
the two groups of patients, the hazard at time t for a patient on the new treatment is
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proportional to the hazard at that same time for a patient on the standard treatment.
This proportional hazards model can also be expressed as:
hN(t) = φhS(t) ; ∀t ≥ 0, (2.4.6)
where φ is a constant. The relative hazard φ cannot be negative, and it is thus
convenient to set:
φ = exp(β). (2.4.7)
The β parameters are then the logarithm of the hazard ratio, that is,
β = log φ, (2.4.8)
and any value of β in the range (−∞,+∞) will lead to a positive value of φ.
The models (2.4.3−2.4.5) can be generalised to the situation where the hazard of death
at a particular time depends on the values x1, x2, . . . , xp of p explanatory variables.
The values of these variables will be assumed to have been recorded at the time of
origin of the study. The set of values of the explanatory variables in the proportional
hazards model will be represented by the vector X, so that X = (X1, X2, . . . , Xp)
′
.
Let h0(t) be the hazard function for an individual for whom the values of all the
explanatory variables that make up the vector X are zero. The hazard function for
the ith individual can then be written as:
hi(t) = h0(t)φ(Xi), (2.4.9)
where φ(Xi) is a function of the values of the vector of explanatory variables for the
ith individual.
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2.4.2 Fitting the proportional hazards model
Fitting the proportional hazards model given in equation 2.4.5 to an observed set
of survival data entails estimating the unknown coefficients of the explanatory vari-
ables (X1, X2, . . . , Xp) in the linear component of the model, β1, β2, . . . , βp. The
baseline hazard, h0(t), may also need to be estimated. These two components of the
model can be estimated separately. The β
′
s are estimated first and these estimates
are then used to construct an estimate of the baseline hazard function. This is an
important result, since it means that in order to make inferences about the effects of
p− explanatory variables (X1, X2, . . . , Xp) on the relative hazard, hi(t)h0(t) , we do not
need an estimate of h0(t) (Collett, 2015; Allison, 2010).
The β-coefficients in the proportional hazards model, which are the unknown param-
eters in the model, can be estimated using the method of partial maximum likelihood.
To utilize this method, we first obtain the likelihood of the sample data (Collett,
2015). This is the joint probability of the observed data, regarded as a function of
the unknown parameters in the assumed model. For the proportional hazards model,
this is a function of the observed survival times and the unknown β-parameters in
the linear component of the model. Estimates of the β
′
s are then those values which
are the most likely on the basis of the observed data. These maximum likelihood
estimates are therefore the values which maximise the likelihood function (Collett,
2015).
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2.4.3 The likelihood function for the model
The basis of the argument used in the construction of a likelihood function for the
proportional hazards model is that intervals between successive death times convey
no information about the effect of explanatory variables on the hazard of death. This
is because the baseline hazard function has an arbitrary form, and so it is conceivable
that h0(t), and hence hi(t), is zero in those times or intervals where there are no
deaths. This in turn means that these intervals give no information about the values
of the β-parameters. We therefore consider the probability that the ith individual dies
at some time tj, conditional on tj being one of the observed set of r ordered death
times t1, t2, . . . , tr. If the vector of explanatory variables for the individual who dies
at tj is Xj, this is:
P [individual with variables Xj dies at tj|one death at tj]. (2.4.10)
Next, from the conditional probability result that the probability of an event A given
that an event B has occurred:
P (A|B) = P (A
⋂
B)
P (B)
. (2.4.11)
The expression in 2.4.10 becomes:
P [individual with variables Xj dies at tj]
P [one death at tj]
. (2.4.12)
The numerator of this expression is simply the hazard of death at time tj for the
individual whose vector of explanatory variables is Xj. If it is the i
th individual who
dies at time tj, the hazard function can be written as hi(tj). The denominator is the
sum of the hazards of death at time tj over all individuals who are at risk of death at
this time. This is the sum of the values hl(tj) over those individuals indexed by l in
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the risk set at time tj, R(tj). Consequently, the conditional probability in expression
2.4.11 becomes:
hi(tj)∑
l∈R(tj) hl(tj)
, (2.4.13)
and on using 2.4.12 and 2.4.13, the baseline hazard function in the numerator and
denominator cancels out, and we are left with:
exp(β
′
Xj)∑
l∈R(tj) exp(β
′Xl)
. (2.4.14)
Finally, taking the product of these conditional probabilities over the r death times
gives the likelihood function:
L(β) =
r∏
j=1
exp(β
′
Xj)∑
l∈R(tj) exp(β
′Xl)
, (2.4.15)
in which Xj is the vector of covariates for the individual who dies at the j
th or-
dered death time, tj. The summation in the denominator of this likelihood function
is the sum of the values of exp(β
′
X) over all the individuals who are at risk at time tj.
For censored data which is a common phenomenon with survival data, suppose that
the data consist of n observed survival times, denoted by t1, t2, . . . , tn and that δi de-
notes a censoring indicator which is zero if the ith survival time ti, where i = 1, 2, . . . , n
is right censored, and one if the ith survival time ti is observed for patient i. The
likelihood function in 2.4.15 can then be expressed as:
L(β) =
r∏
j=1
[
exp(β
′
Xj)∑
l∈R(ti) exp(β
′Xl)
]δi
, (2.4.16)
where R(ti) is the risk set at time ti and δi is the indicator variable that takes a
value 1 if the outcome of interest is observed at ti. The corresponding log-likelihood
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function is given by:
log L(β) =
n∑
i=1
δi
β ′Xi − log ∑
l∈R(ti)
exp(β
′
Xl)
 . (2.4.17)
The maximum likelihood estimates of the β-parameters in the proportional hazards
model can then be found by maximising this log-likelihood function using numerical
methods such as the Newton Raphson Procedure (Collett, 1994).
2.5 Extensions of the proportional hazards model
In the past few years, the Cox proportional hazards model has been extended to the
Bayesian framework and also the generalised additive models (GAMs) framework.
Brief reviews of these frameworks are covered in the next sections.
2.5.1 Bayesian proportional hazards model
This model is premised on the proportional hazards modelling framework and adds
the Bayesian flavour in estimating the model coefficients. In this approach, the partial
likelihood function in equation 2.4.16 is used as the likelihood function in the posterior
distribution (Sinha, Chen, & Ibrahim, 2003).
2.6 Quantile regressions and ordinary least squares
Quantile regressions as pioneered by Koenker and Basset (Koenker & Bassett Jr,
1978) seeks to complement classical linear regression methods. The main aim of re-
gression analysis is to analyse the behaviour of a dependent variable Yi given some
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explanatory variables Xi. The ordinary least squares (OLS) methods are used to ob-
tain the parameter estimates through the minimisation of the error sums of squares.
The result is an approximation of the mean function of the conditional distribution of
the dependent variable. The parameters estimated through the OLS method achieves
the property of BLUE (best, linear, and unbiased estimators), if the following assump-
tions hold, that is: the explanatory variables X are non-stochastic; the expectation
of the error term i is zero (E(i) = 0); homoscedasticity, that is, the variance of the
error terms i is a constant (V ar(i) = σ
2) and no auto-correlation of error terms
(Cov(i, j) = 0 ∀ i 6= j).
However, in most cases, one or more of these assumptions are violated, leading to
OLS parameter estimates not being BLUE. Generally quantile regressions perform
better than the classical linear regression methods where the error terms are not con-
stant, that is, violating the homoscedasticity assumption; the focus is on the tails of
the distribution rather than the mean as a measure of location and where data has
extreme outliers (skewed data) because OLSs are too sensitive to extreme outliers
leading to significant distortion of results.
2.7 Quantile regression modelling
Quantile regression as introduced by Koenker and Basset (Koenker & Bassett Jr,
1978) may be viewed as a natural extension of the classical least squares estimation
of conditional mean models to the estimation of an ensemble of models for condi-
tional quantile functions. To know the relationship between y and x, the classical
least-squares regression requires the conditional mean function, that is, the function
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that explains how the mean of y changes with the vector of explanatory variables
x. However, according to Frisch (1934) and Koopmans (1937), it is the systematic
component around which y fluctuates due to an erratic component that is needed to
explain this relationship (Frisch, 1934; Koopmans, 1937).
Crucially, the error component is assumed to have precisely the same distribution
regardless of the values taken by the vector x. This is referred to as a pure location
shift model since it assumes that x affects only the location of the conditional dis-
tribution of y, not its scale, or any other aspect of its distributional shape. Given
this to be the case, an estimated model of the conditional mean function, supple-
mented perhaps by an estimate of the conditional dispersion of y around its mean is
sufficient. Furthermore, when the requirement that the errors are Gaussian is added,
least squares methods deliver the maximum likelihood estimates of the conditional
mean function (Koenker & Hallock, 2001b).
However, the argument is that there is more to biometric, biostatistics and epi-
demiological modelling than what is stipulated in the usual location shift modelling
framework. Covariates may influence the conditional distribution of the response in
a myriad other ways such as expanding its dispersion as in traditional models of het-
eroscedasticity, stretching one tail of the distribution, compressing the other tail and
even inducing multimodality. An explicit investigation of these effects via quantile
regression can provide a more nuanced view of the stochastic relationship between
variables, and therefore a more informative empirical analysis.
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2.7.1 Fundamentals and features of the quantile regression
Gilchrist (2001) describes a quantile as ”simply the value that corresponds to a speci-
fied proportion of an (ordered) sample of a population” (Gilchrist, 2001). A commonly
used example of a quantile is the median, M, which is the proportion of 0.5 of the
ordered data. This relates to a quantile with a 0.5 chance of occurrence. Quantiles
hereby mark the boundaries of equally sized, consecutive subsets. Quantile regres-
sion therefore generalises the concept of a univariate quantile to a conditional quantile
given one or more covariates (Chen, 2013).
For a continuous random variable Y with probability distribution given in the follow-
ing equation:
F (y) = P (Y ≤ y), (2.7.1)
which states that for the distribution function FY (y) one can determine, for a given
value y the probability F (y) = τ of occurrence. Now if one is dealing with quantiles,
one wants to do the opposite, that is, one wants to determine for a given probability
τ of the sample data set the corresponding value y. A τ th-quantile refers in a sample
data to the probability τ for a value y, that is:
FY (yτ ) = τ. (2.7.2)
Another form of expressing the τ th-quantile mathematically is as follows:
yτ = F
−1
Y (τ) (2.7.3)
where yτ is such that it constitutes the inverse of the function FY (y) for a probability
τ . Note that there are two possible scenarios. The first scenario is, if the distribution
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function FY (y) is monotonically increasing, quantiles are well defined for every τ ∈
(0; 1). The second scenario states that if a distribution function FY (y) is not strictly
monotonically increasing, there are some τ ′s for which a unique quantile cannot be
defined. In this last case, one uses the smallest value that y can take on for a given
probability τ . Then for any τ ∈ (0; 1), the τ th quantile of Y for both scenarios is
defined as follows:
Q(τ) = inf {y : F (y) ≥ τ} = yτ = F−1Y (τ). (2.7.4)
That is yτ is equal to the inverse of the function FY (τ) which in turn is equal to the
infinimum of y such that the distribution function FY (y) is greater or equal to a given
probability τ , that is, the τ th-quantile. In particular, the median is Q(1
2
), the first
decile Q( 1
10
) and the first quarter Q(1
4
). The quantile function provides a complete
characterisation of Y , just like the distribution function F .
2.7.2 Quantile regression model
The linear conditional quantile regression model can be specified as follows:
Q(τ |X = x) = β0τ + β1τX1i + · · ·+ βpτXpi + i. (2.7.5)
where
β0τ is the intercept for the quantile model at the τ
th level.
β1τ , . . . , βpτ are the coefficients for the P covariates at each probability τ .
X1i, . . . , Xpi are the P independent covariates and
is are the error terms.
This model can also be expressed as a generalised linear model in the form:
Q(τ |X = x) = X ′β(τ ) + i. (2.7.6)
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where:
X
′
is the design matrix and
β(τ) is the vector of parameters.
This model is analogous to the OLS regression model, hence the estimation of the pa-
rameters is via the minimisation procedure. That is for a random sample {y1, y2, . . . , yn}
of Y it is well known that the sample median is the minimiser of the sum of the ab-
solute deviations:
min∈R
n∑
i=1
|yi − |. (2.7.7)
2.7.3 Censored quantile regressions
Linear censored quantile regressions (CQR), introduced by Powell in 1984 allows for
semi-parametric estimation of quantile regressions for a censored regression model in
a robust way (Chernozhukov & Hong, 2011). Censored quantile regression (CQR) is
robust against misspecification of the error terms since only fairly weak assumptions
on the error terms are required.
Let the possible observed duration be right censored, that is, the observed com-
pleted duration Ti be given by Ti = min {T ∗i , yci}, where T ∗i is the true duration of
the spell and yci is the spell specific threshold value or censoring point, beyond which
the spell cannot be observed. For the proportional hazards model (PHM), this can
be incorporated in the maximum likelihood estimation (Woodridge, 2002).
In contrast, CQR requires the knowledge of yci irrespective of whether the obser-
vation is right censored or not. CQR provides consistent estimates of the quantile
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regression coefficients βτ in the presence of fairly general forms fixed censoring. The
known censoring points can either be deterministic or stochastic and they should not
group in a certain way or around the true quantile regression line. Estimating the
linear CQR model involves minimising the following distance function:∑
i=1
ρτ (ln(Ti)−min(X ′iβτ , yci)), (2.7.8)
with respect to βτ , where ρτ (z) = τ.|z| for z ≥ 0 and ρτ (z) = (1 − τ).|z| for z < 0
and yci denotes the known observation specific censoring points. A quantile regres-
sion without censoring is nested as the special case with yci = +∞.
The censored quantile regression estimator βˆτ is
√
N -consistent and asymptotically
normally distributed (Powell, 1984). A crucial feature of this result is that the asymp-
totic distribution depends only upon those observations where the fitted quantiles are
not censored.
The actual calculation of the CQR estimator based on individual data is numeri-
cally very difficult since the distance function 2.7.7 which is to be minimised is not
convex. For heteroscedasticity-consistent inference, bootstrapping is often resorted
to through the use of the design-matrix-bootstrapping. The covariance matrix of the
CQR estimates across quantiles can also be estimated.
2.7.4 Quantiles via optimisation
Quantiles seem inseparably linked to the operations of ordering and sorting the sample
observations that are usually used to define them. So it comes as a mild surprise to
observe that quantiles can be defined through a simple alternative expedient as an
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optimisation problem or a linear programming problem. Just as we can define the
sample mean regression function as the solution to the minimization of the sum of
squared residuals, we can define the median regression function as the solution to
the problem of minimising the sum of the absolute residuals (Koenker & Hallock,
2001b). The symmetry of the piecewise linear absolute value function implies that the
minimisation of the sum of absolute residuals must equate to the number of positive
and negative residuals, thus assuring that there are the same number of observations
above and below the median. Now for the other quantiles, since the symmetry of
the absolute value yields the median, perhaps minimising the sum of asymmetrically
weighted absolute residuals, simply giving differing weights to positive and negative
residuals would give yield to the quantiles. The case here is of solving the following
linear programming problem or minimisation problem:
minβ∈R
n∑
i=1
ρτ (yi − (xi, β)). (2.7.9)
Where ρτ serves as a check function and is defined by:
ρτ (x) =
{
τ ∗ x if x ≥ 0
(τ − 1) ∗ x if x < 0
}
. (2.7.10)
This check function ensures that:
1. All ρτ are positive, and
2. The scale is according to the probability τ .
The resulting minimisation of equation 2.7.9, when (x, β) is formulated as a linear
function of parameters can then be solved very efficiently by implementing linear
programming methods.
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2.7.5 Features that characterise quantile regressions
The following features characterise quantile regression methods and differentiate them
from other regression methods:
1. The entire conditional distribution of the dependent variable Y can be charac-
terised through different values of τ .
2. Heteroscedasticity can be detected.
3. If the data is heteroscedastic, median regression estimators can be more efficient
than the mean regression estimators.
4. The minimisation problem can be solved efficiently by linear programming
methods, making estimation easy.
5. Quantile regression functions are robust with regards to outliers.
The quantile regression methods however have their own disadvantages and these
include not being able to deal with time-variant covariates, having no support for
competing risk framework yet and also not being able to account for unobserved
heterogeneity (Fitzenberger & Wilke, 2005).
2.7.6 Quantile regression model estimation
Consider data in the form xTi , yi, for i = 1, 2, . . . , n where yi are the independent
scalar observations of a continuous random variable with common cumulative dis-
tribution function Fy, whose shape is not exactly known, x
T
i are row p-vectors of a
known design matrix X.
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The linear conditional quantile functions are defined as:
Qyi(τ |xi) = xTi β, (2.7.11)
where i = 1, 2, . . . , n, 0 < τ < 1, Qyi(.) = F
−1
yi
(.), and β ∈ Rp is a column vector of
length p with unknown fixed parameters. We refer to the τ th regression quantile any
solution β∗, β∗ ∈ Rp, to the minimisation problem:
minβ∈RpVn(β) ≡
∑
i∈(i:yi≥xTi β)
τ |yi − xTi β|+
∑
i∈(i:yi<xTi β)
(1− τ)|yi − xTi β|. (2.7.12)
In order to highlight the τ -distributional dependency, the parameter β and the solu-
tion β∗ should be indexed by τ , that is, β(τ) and β∗(τ). The objective function 2.7.12
presents a minimisation problem otherwise known as a linear programming problem,
thus the simplex method for linear programming problems is then used to determine
the optimal β solutions for the objective function (Koenker & d’Orey, 1985).
2.8 Missingness and imputations
Missing covariate values is a common problem in survival data research (Satty, 2014).
Standard statistical methods have been developed to analyse rectangular data sets.
The rows of the data matrix represent units, also called cases, observations, or subjects
depending on context, and columns represent variables measured for each unit (Little
& Rubin, 1987). The implications of missingness include:
1. Loss of efficiency: we collect and analyze less data than originally planned.
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2. Unbalanced datasets: not all subjects have the same number of measurements
from the study.
3. Potential bias: missingness may depend on outcome hence affecting the esti-
mates for the different model parameters.
2.8.1 Missingness mechanism
A major challenge for the analysis of survival and longitudinal data outcomes is the
fact that these outcomes are often incomplete. Missing data in these studies occur in
basically two ways. The first type is when patients are missing at intermittent times,
meaning that other measurements are observed following missing values. The second
type of missing data occurs when data is not available for a subject after some time
point, and the patient is said to have dropped-out of the study. The main concern in
longitudinal as well as in survival analysis with missing data arises when there is an
association between the longitudinal profile and the missing process (Andrinopoulou,
2014). The appropriateness of different methods of analysis of incomplete data is
determined by the missing data mechanism. Specifically, there are three types of
mechanisms namely:
1. Missing completely at random (MCAR): when the probability that the responses
are missing, is unrelated to the longitudinal or survival outcome. For example
if a patient dies from any other cause except the cause of interest in the study
(Andrinopoulou, 2014).
2. Missing at random (MAR): when the probability of missingness depends on the
set of observed longitudinal responses, but is unrelated to the outcomes that
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should have been obtained (Andrinopoulou, 2014).
3. Missing not at random (MNAR): when the probability that the longitudinal or
survival responses are missing depends on observed and unobserved data.
According to Little and Rubin (Little & Rubin, 1987), there are three main procedures
for treating missing data in data analysis. These procedures are briefly discussed
below:
1. Procedures based on completely recorded units (complete case analysis),
2. Imputation based procedures, and
3. Weighting procedures.
2.8.2 Procedures based on completely recorded units
When some variables are not recorded for some of the units, a simple expedient
procedure is to discard incompletely recorded units and to analyze only the units with
complete data. This procedure is generally easy to carry out and may be satisfactory
with small amounts of missing data. However, this method can lead to serious biases
and usually it is not very efficient (Little & Rubin, 1987).
2.8.3 Imputation based procedures
The missing values are filled in and the resultant completed data are analyzed by
standard methods. Commonly used procedures for imputation include hot deck im-
putation, where recorded units in the sample are substituted using a response from
a patient with a similar profile; mean imputation, where means from sets of recorded
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values are substituted; and regression imputation, where the missing variables for a
unit are estimated by predicting values from the regression on the known variables
for that unit (Little & Rubin, 1987).
Hot deck imputation
This can broadly be defined as a method where an imputed value is selected from
an estimated distribution for each missing value; in contrast with mean imputation,
where the mean of the distribution is substituted (Little & Rubin, 1987).
Mean imputation
This is the imputation procedure where means from the responding units in the
sample are substituted for missing values. The means may be formed within cells
analogous to the weighting cells formed for weighting procedures (discussed below).
Mean estimates leads to estimates similar to those found by weighting, provided the
sampling weights are constant within classes (Little & Rubin, 1987).
Regression imputation
This imputation procedure replaces missing values by predicted values from a regres-
sion of the missing item on items observed for the unit, usually calculated from units
with both observed and missing variables present. Mean imputation can be regarded
as a special case of regression imputation where the predictor variables are dummy
indicator variables for the cells within which the means are imputed (Little & Rubin,
1987).
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Multiple imputation
Multiple imputation methods (Rubin, 1978, 1987) impute more than one value for
the missing items. An important limitation of single imputation methods is that
standard variance formulas applied to the filled in data systematically underestimate
the variance of estimates, even if the model used to generate the imputations is
correct (Little & Rubin, 1987). Multiple imputation procedures or methods allow
valid estimates of the variance of estimates to be calculated using standard complete
data procedures.
2.8.4 Weighing procedures
Randomisation inferences from sample survey data without nonresponse are com-
monly based on design weights, which are inversely proportional to the probability
of selection. Weighting procedures modify the weights in an attempt to adjust for
non-response.
2.9 Summary
This chapter reviewed relevant literature on HIV/AIDS in Zimbabwe and Namibia.
Survival analysis and modelling techniques were also reviewed based on the focus of
this study. A brief overview on dealing with missing data was also done. The next
chapter, that is, Chapter 3, discusses the methodology used in this study.
 
 
 
 
Chapter 3
Methodology
In this chapter the target populations, samples, variables, data collection and tools
used in the collection process are discussed for both countries, that is, Zimbabwe
and Namibia. The procedures that were utilized in the modelling of the datasets
are highlighted in this chapter. The flowchart in Figure 3.1 indicates the different
datasets that were used for the purposes of this study. The analysis methods and
chapters in which these analyses were done are also highlighted. The details of each
of the datasets are discussed in the sections below.
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Figure 3.1: Datasets flowchart
3.1 Namibia HIV/AIDS data
A single paediatric dataset from Namibia was used in this research. This dataset was
obtained from Katutura hospital, Windhoek.
3.1.1 Katutura hospital paediatric HIV/AIDS dataset
A retrospective cohort study design was conducted for children who initiated ART
between 01 January 2006 and 31 December 2010. All children living with HIV/AIDS
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below the age of 15 and who started taking ARVs from Katutura Hospital within the
period of 2006 - 2010 were included in the sample. The target population was all the
children under 15 years who are on Katutura Hospital’s records as ART paediatric
patients regardless of the period of their ART initiation. The sampling frame consti-
tuted about 1605 paediatric patients and from these a final sample of 813 children was
selected from those who initiated ART between 01 January 2006 and 31 December
2010. All children who did not have complete information such as missing date of
initiation or date of last visit to hospital were dropped from the study. This data was
obtained from the hospital’s Management Information System database (MIS) with
the help of the hospital data clerks. The study subjects were followed from initiation
to December 2014. The setting for this study was Katutura State Hospital located
in Windhoek, the capital city of Namibia. The hospital has an HIV/AIDS section
which deals with all aspects of HIV case management and care, that is, from enrol-
ment, counselling, initiating, follow-up and giving out medication to patients during
their scheduled visits to the hospital.
For the purposes of this study and also due to the limitations associated with sec-
ondary data collected from the Ministry of Health and Social Services’ management
information systems database, the study covariates were limited to paediatric pa-
tients’ gender, baseline World Health Organisation’s (WHO) clinical stages of HIV,
baseline functional status, baseline age category and absolute CD4 count. Functional
status is an individual’s ability to perform normal daily activities required to meet
basic needs, fulfill usual roles, and maintain health and well-being (WHO, 2004).
According to WHO (2004) functional status is defined as:
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(a) Working if person is able to perform usual work in or out of the house, harvest,
go to school or, for children, normal activities or playing.
(b) Ambulatory if person or child is able to perform activities of daily living but
not able to work or play.
(c) Bedridden if person or child is not able to perform activities of daily living.
Absolute CD4 count was classified according to the age of the child and it has two
categories, CD4 count below threshold and CD4 count above threshold.CD4 count
below threshold was defined for infants as CD4 count less than 1500/mm3, for age
12−35 months as CD4 count less than 750/mm3, for age 36-59 months as CD4 count
less than 350/mm3, and for age >= 60 months as CD4 count less than 200/mm3
(Bong, et al., 2007).
Ethical clearance was obtained from the Ministry of Health and Social Services and
approval for data collection was granted by the Provincial Medical Doctor (PMD)
stationed at Katutura Hospital (See Appendix A.2). The database only captured
patient case numbers and not names or any other information that may directly be
linked to the patient. The data was also not shared with any third party hence
confidentiality was maintained.
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Variables of interest
The variables of interest in this dataset are shown in Table 3.1 below and they are
all measured at baseline:
Table 3.1: Paediatric dataset variables
Variable Variable levels
WHO staging
Stage 1
Stage 2
Stage 3
Stage 4
Paediatric Gender
Male
Female
Functional status
Ambulatory
Bedridden
Working
Age category
Less than 1 year
1− < 5 years
5− < 15 years
Absolute CD4 count
CD4 below threshold
CD4 above threshold
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3.2 Zimbabwe HIV/AIDS data
The other dataset that was used for purposes of this study was from Zimbabwe. A
retrospective research design was utilized in this study hence secondary data was
collected. The dataset was collected from Medicin Sans Frontiers(MSF) Bulawayo
hospital. The details and variables to be used in the study are discussed in the
section below.
3.2.1 MSF Bulawayo dataset
MSF is a non-governmental organisation (NGO) that deals with humanitarian sup-
port in developing countries. MSF has been working in Zimbabwe since the year
2000 and it is currently running comprehensive HIV/AIDS programmes in health
centers in Beitbridge, Buhera, Bulawayo, Chikomba, Gutu, Gweru and Tsholostho.
This research study used data from the Bulawayo hospital MSF health center. The
organisation is working with the Ministry of Health and Child Welfare (MoHCW) on
efforts to reduce HIV/AIDS infection and mortality through the different HIV/AIDS
programmes in Zimbabwe. One such programme is the anti-retroviral (ARV) treat-
ment programme. As of 2010, the MSF programme has provided treatment to more
than 34 000 Zimbabweans. The organisation enrols HIV/AIDS patients onto it’s
ARV programme and the patients are given a schedule of the intervals at which they
can come and replenish their ARV medication as well as having check-ups and tests.
At every visit the patient information in the ART register is updated on the vari-
ables of interest that are measured over time such as weight, CD4 count, adherence
and haemoglobin (HB) levels. The baseline patient information is also captured at
treatment initiation. Date of current (last) visit is also noted and this was used to
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determine the patient’s duration on ARV treatment. The data were accessed from
an MS Access database where the electronic information from the ART registers was
captured and stored. The patients in the database were identified via a unique iden-
tification number hence no names or addresses were used.
The target population was adults aged 15 years and above from Bulawayo hospi-
tal MSF center who enrolled for ARV treatment in the period 2004 to 2010. For
inclusion into the retrospective cohort study sample, a patient had to be alive on
01 January 2004 and receiving ARVs from MSF Bulawayo hospital or started ART
treatment at the same hospital in 2004 but before 01 January 2005. A total final
sample of 1134 patients was followed over six years. Data were manipulated and
new variables were created, that is, the survival time variable was obtained from the
difference between the last known hospital visit date and the date the patient was
initiated on ART. A censor variable was also created which catered for identifying
those patients whose event of interest (death) was observed or failure to follow-up as
well as those who were alive at the end of the study period (2010). Demographic,
clinical and serological variables all recorded at initiation of treatment were then used
in the study to identify prognostic risk factors for survival of ART patients using a
censored quantile regression model.
Ethical clearance was granted by the ministry of health and child welfare as well
as the MSF operations research unit (See Appendix A.1).
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Variables of interest
The variables of interest in this dataset are shown in Table 3.2 below and they are
all measured at baseline:
3.3 Data imputation
Missing covariate values are a common problem in survival data and analysis re-
search (Satty, 2014). Since this study analysed survival data, where some covari-
ates had missing values, we applied the multiple imputation procedures to make the
data complete for analysis and hence we reduced biases associated with incomplete
datasets. For all the datasets, multiple imputation procedures were done, where nec-
essary, on the missing data and then the full dataset after imputation was used in
the inferences.
3.4 Proportional hazards regression model param-
eter estimation
Cox’s proportional hazards model was estimated for the paediatric dataset. The
Bayesian proportional hazards model was also fitted for the same dataset. The in-
ferential aspects for the Bayesian proportional hazards model were then compared to
the CQR model results with a view to determine prognostic risk factors at different
survival time points for patients on ART treatment. The SAS statistical package was
used for this estimation.
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Table 3.2: MSF Bulawayo dataset variables
Variable Variable levels
WHO staging
Unspecified
Stage 1
Stage 2
Stage 3
Stage 4
Gender
Male
Female
Profession
Unemployed
Formally employed
Self employed
Other
Marital status
Single
Married
Widowed
Divorced
Age category
Lower than 35 years (15− < 35 years)
Between 35 and 50 years
Above 50 years
Weight category
Lower than 45 kgs
Between 45 and 60kgs
Above 60kgs
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The global test for the proportionality assumption and the the Schoenfeld residual
plots were used to assess whether there was any violation of the proportional hazards
assumption.
3.5 Censored quantile regression model parameter
estimation
Censored quantile regression (CQR) models were estimated for different quantile val-
ues, or τ values. These τ values covered the spectrum on which the quartiles are
described. The standard errors that were used in the 95% confidence interval es-
timates of these parameters were obtained through using the bootstrap resampling
methods. The p-values were used to determine the significant prognostic risk factors
that influences survival time at different time points. The graphical representations
were used to highlight the effect of the risk factors across all the quantile values of
the survival time distribution. The CQR model was fitted to the paediatric dataset
to identify the effect of each risk factor at different quantile points of the patients’
survival times. The results from this model fitting were compared to those from the
Bayesian proportional hazards model. The SAS statistical package was used for this
estimation.
The paediatric dataset was also used for the comparison between the Cox’s pro-
portional hazards and the CQR models. This was done to highlight that the effects
of the risk factors as estimated by the CQR method vary across the survival time
distribution whilst they seem constant from the Cox’s proportional hazards model.
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The CQR model was estimated for the MSF Bulawayo hospital adult dataset to
determine risk factors for shorter survival times. The results are discussed and con-
clusions given.
3.6 Summary
This chapter discussed the two datasets from Namibia and Zimbabwe that were uti-
lized in this study as well as the research design. The study populations were also
highlighted. The modelling techniques implemented were highlighted together with
the purposes they intended to achieve. The next chapter, that is, Chapter 4, im-
plements the Cox’s proportional hazards model on the paediatric dataset in order to
determine survival time risk factors.
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Survival analysis of HIV positive
adolescents and paediatrics on
antiretroviral treatment at
Katutura hospital, Windhoek,
Namibia
This chapter has been submitted for publication as:
Maposa, I. and Blignaut, R.J. (2016). Survival Analysis of HIV Positive adoles-
cents and Paediatrics on Antiretroviral Treatment at Katutura Hospital, Windhoek,
Namibia. Journal of Social Aspects of HIV/AIDS.
Submission ID:RSAH-2016-0002
Status: Under review.
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4.1 Summary
The scourge of HIV/AIDS has been around for the past three decades but still there
is no cure in sight, hence care and therapy are the best way of dealing with the dis-
ease. Children have not been spared from the wrath of this epidemic and millions in
Southern African Development Countries (SADC) and the African continent are in
dire need of treatment. Namibia also has not been spared from this either.
The purpose of this study is to analyze and determine the risk factors that negatively
affect survival of children younger than 15 years who are on antiretroviral treatment
(ART) in Windhoek. The study also seeks to identify the survival prospects of these
children on ART, given the different risk factors. A retrospective cohort study design
was conducted for children who initiated ART between 01 January 2006 and 31 De-
cember 2010 at Katutura Hospital in Windhoek, Namibia. All HIV/AIDS positive
children below 15 years who started ART at Katutura Hospital between January 2006
and December 2010 were included in the study.
The Kaplan-Meier survival functions were used to assess survival chances of these
adolescent and paediatric patients given different risk factors. The log-rank tests
were used to identify any significant differences in survival for different factor groups.
The proportional hazards model was used to determine the significant risk factors
for survival of patients on antiretroviral treatment. The log-rank tests indicate the
likelihood of significant differences in the chances of survival for children who were
initiated on ART treatment in different WHO stages and also in different functional
statuses. Age category was found to be a significant risk factor and being an infant
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was associated with a significant negative effect on survival time.
Improvements and targeted interventions are recommended on paediatric ART pa-
tients follow-up programmes especially on infants. Special attention should be given
to children who initiate in stage IV as well as in the bedridden functional status so
that their survival prospects may be improved.
4.2 Introduction and background
According to the World Health Organisation (WHO) report on treatment of children
living with HIV, an estimated 3.2 million children were living with HIV at the end of
2013, and most of these were in Sub-Saharan Africa. The report also indicates that
the majority of these children acquire HIV from their HIV-infected mothers during
pregnancy, birth or breastfeeding. The WHO believes that with efficacious interven-
tions, the risk of mother-to-child HIV transmission can be reduced to as low as 2%.
Unfortunately, according to the report, such interventions are still not widely acces-
sible or available in most resource-limited countries like those in the SADC region
where the burden of HIV infection is highest. Thus these children who are already
infected with HIV would need to be enrolled in effective treatment for them to stay
healthy (WHO, 2014).
The WHO report on treatment of children living with HIV also highlights that the
number of children (younger than 15 years) receiving ART in low- and middle-income
countries more than doubled from 2009 to 2013, from 355 000 to 740 000. At the
end of 2013, less than one quarter (23%, range 21− 25%) of children living with HIV
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were receiving ART in low and middle income countries compared with more than
one third (37%, range 35− 39%) of adults living with HIV (WHO, 2014).
In the absence of antiretroviral therapy (ART), over 50% of HIV infected infants
progress to AIDS and death by 2 years (Newell et al., 2004). The introduction of
ART has dramatically improved health outcomes of HIV-infected children (Gibb &
Giaquinto, 2000). However, according to the UNAIDS 2013 report, at the end of
2012, only 35% of eligible children in low and middle-income countries had initiated
ART (UNAIDS, 2013).
Paediatric HIV infection is still a leading cause of death among children in devel-
oping countries, with mortality rates highest during infancy (Thorne et al., 2007). In
Namibia, HIV/AIDS is one of the leading causes of death and is estimated to cause
23% of the mortality (PEPFAR, 2012). However, among children under 15 years,
HIV/AIDS is estimated to be responsible for 8% of the deaths ranking it among the
top three causes of deaths in Namibia (MoHSS, 2008).
Paediatric HIV care started in 2002 and has gained traction over the years. Around 14
000 children (aged 0-14) are estimated to be living with HIV (PEPFAR, 2012; WHO,
2014) and the antiretroviral therapy coverage for these children in Namibia was es-
timated at 87% in 2010 (UNICEF, 2011). According to Leroy and co-researchers,
characteristics at ART initiation and short-term outcomes (mortality, retention in
programme) are evolving in paediatric ART programmes (Leroy et al., 2013). Many
reports show decreased mortality in children after ART initiation but despite this,
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some children are started on ART with an advanced disease. In addition, programmes
that have rapidly scaled-up ART have, as in adults, high loss to follow-up (LTFU)
rates. In adults, high rates of LTFU correspond to underreported mortality, suggest-
ing that in children a significant proportion of child mortality may be unseen as well.
In Namibia, there is insignificant documentation on the factors that are associated
with mortality and loss to follow-up in children initiated on ART treatment and this
needs investigation.
The effects of socio-demographic, clinical and immunological factors on survival of
HIV positive children after initiation of ART were studied in other low to medium
income countries. However, according to Kedir and co-researchers, the findings of
the studies are not consistent. For instance, in studies conducted on cohorts of HIV
positive children in Cote dIvoure, Malawi and Zambia, only low weight-for-height and
a low CD4% were found to have a significant negative effect on survival of children
after ART initiation (Kedir, Desta, & Fesseha, 2014). Also in another large cohort
of HIV positive children of Zambia, besides a low CD4% and a low weight-for-height
z-score (WHZ), younger age and low haemoglobin level were also found to have a
significant negative effect on survival after initiation of ART (Kedir et al., 2014).
The scarcity of this kind of information in the Namibian context was another reason
for conducting this study. In this study the children on ART at Katutura Hospital
were followed for a period between four and nine years to estimate their survival
status. Though ART services for children started in 2002 in Namibia, there are no
studies on survival analysis and factors that affect the survival of children on ART
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in the country as well as the study area. This further highlights the need for local
evidence to estimate the survival patterns and also determine the factors affecting
the survival of children on ART at Katutura Hospital in Windhoek.
4.3 Materials and methods
4.3.1 Study design, sample and setting
A retrospective cohort study design was conducted for children who initiated ART
between 01 January 2006 and 31 December 2010. All children living with HIV/AIDS
below the age of 15 and started taking ARVs from Katutura Hospital within the
period of 2006 - 2010 were included in the sample. The target population was all the
children under 15 years who are on the Katutura Hospital records as ART paediatric
patients regardless of the period of their ART initiation. All children who did not
have complete information such as missing date of initiation or date of last visit to
hospital were dropped from the sample. The population constituted about 1605 pae-
diatric patients and from these a final sample of 813 children was selected from those
who initiated ART between 01 January 2006 and 31 December 2010. This sample
size was established through the use of EpiCalc for sample size calculation and then
adjusting the value for covariate item missingness. This dataset was obtained from
the hospital’s Management Information System database (MIS), with the help of the
hospital data clerks. The study subjects were followed from initiation to December
2014.
The setting for this study was Katutura State Hospital located in Windhoek, the
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capital city of Namibia. The hospital has an HIV/AIDS section which deals with
all aspects of HIV case management and care, that is, from enrolment, counselling,
initiating, follow-up and giving out of the drugs to patients during their scheduled
visits to the hospital.
4.3.2 Statistical analysis and data quality
Survival analysis was used in this study. The term survival analysis pertains to a
statistical approach designed to take into account the amount of time an experimental
unit contributes to the study before experiencing an event. The analysis consists of
following the subject until death or lost to follow-up. For this study, the time to
death was the outcome variable. The time to death was assessed for subjects from
the date of initiation to the date of death before 31 December 2014 (the end of the
study period). Those who did not experience the event of interest before the end of
the study were considered censored together with those who were lost to follow-up.
For the lost to follow-up paediatric patients, their time at risk was taken up to the
last visit date. Data on HIV related deaths for these children on ART was captured in
the database after being informed by physicians and/or relatives. The deaths which
the hospital could not confirm as HIV related were not recorded, thus such children
were considered as censored in this study. This is one of the main challenges with
data from resource limited countries like Namibia as this tends to underestimate the
actual HIV related deaths. The baseline socio-economic, immunological and clinical
variables were measured and recorded at initiation. These were then used in the
analysis either as they were collected or used to create indicator variables that are
recommended when dealing with paediatric survival analysis. The Kaplan-Meier test
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was used to estimate survival after the initiation of ART, and the log-rank tests were
done to compare the survival prospects of different groups. The variables with p-
value less than 20 percent in log-rank tests were selected as potential risk factors
for use in the multivariate Cox proportional hazards model. The variables were also
tested against the proportionality assumption and all that fulfilled the assumption
through the Kaplan Meier survivor curves were included in the Cox’s model. The
significant variables in the multiple Cox proportional hazards model (equation 2.4.5)
were included in the final model. Goodness-of-fit tests were performed on the final
model using the Cox-Snell method. A significance level of five percent was used.
The proportional hazards assumption was also checked for the statistically significant
variables included in the final model using the re-estimation based method and none of
the variables in the final model violated the proportionality assumption. Data quality
for this study was enhanced by focussing on the paediatric patients who fulfilled the
defined study design and who were under the age of 15 at initiation. Quality was also
assured by dropping all the cases that did not have complete information especially
for the measurement of survival time. The collected data was cleaned, coded and
then analysed using SAS version 9.4 (SAS Institute Inc, 2013).
4.3.3 Covariate description
For the purposes of this study and also due to the limitations associated with sec-
ondary data collected from the Ministry of Health and Social Services management
information systems database, the study covariates were limited to the paediatric
patient’s gender, baseline World Health Organisations (WHO) clinical stages of HIV,
baseline functional status, baseline age category and absolute CD4 count. Absolute
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CD4 count was classified according to the age of the child and it has two categories,
CD4 count below threshold and CD4 count above threshold. For these variables and
their categories see Table 3.1 and paragraph 3.2.1 for CD4 threshold definitions.
4.3.4 Ethical clearance
Ethical clearance was obtained from the Ministry of Health and Social Services and
approval for data collection was granted by the provincial medical doctor (PMD) sta-
tioned at Katutura Hospital. As the study was done using secondary data, individual
paediatric patients’ consent was not necessary since the database only captured pa-
tient identification numbers and not names or any other information that may directly
be linked to the patient. The data was also not shared with any third party hence
confidentiality was maintained (See Appendix A.2).
4.4 Results and analysis
4.4.1 Descriptive results and analysis
A total of eight hundred and thirteen (813) records of children under the age of
fifteen who initiated antiretroviral treatment (ART) between 01 January 2006 and
31 December 2010 were included for this study. Table 4.1 and Table 4.2 show the
distribution and median survival times for paediatrics and adolescents on ART in
each category.
From Table 4.1, two hundred (24.6%) were infants below one-year, three hundred and
three (37.3%) were between one and five years, whilst three hundred and ten (38.1%)
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Table 4.1: Distribution of paediatric and adolescent ART patients
Risk factor variable n Percent(%)
Clinical stage
Stage 1 184 25.5
Stage 2 194 26.9
Stage 3 283 39.3
Stage 4 60 8.3
Absolute CD4 count
CD4 count below threshold 430 53
CD4 count above threshold 382 47
Age category
< 1 year 200 24.6
1− < 5 years 303 37.3
5− < 15 years 310 38.1
Functional status
Ambulatory 85 11.2
Bedridden 12 1.6
Working 659 87.2
Gender
Female 412 50.7
Male 401 49.3
were five and above but below fifteen. Four hundred and twelve (50.7%) of these
children were female whilst four hundred and one (49.3%) were male.
The majority of children, two hundred and eighty-three (39.3%), initiating on ART
at Katutura Hospital during the period under study were in clinical stage III of HIV
infection whilst only sixty (8.3%) initiated with a clinical stage IV condition. One
hundred and eighty-four (25.5%) and one hundred and ninety-four (26.9%) initiated
in clinical stages I and II respectively. Four hundred and thirty (53%) initiated ART
with CD4 count below threshold whilst three hundred and eighty-three (47%) had
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their CD count above the threshold values (refer to section 3.2.1 for the threshold
definitions or (Bong et al., 2007)). In terms of the functional status at which these chil-
dren started treatment on, the majority, six hundred and fifty-nine (87.2%), started
in a working functional condition whilst just twelve (1.6%) and eighty-five (11.2%)
were in the bedridden and ambulatory functional conditions respectively.
Table 4.2 shows that the median survival time for children who initiated ART in
Table 4.2: Median survival times by baseline clinical stage, functional status and age
category
Risk factor variable n Percent(%) Median(days) IQR in days
Clinical stage
Stage 1 184 25.5 1591 336.5-2206
Stage 2 194 26.9 2134 609-2867
Stage 3 283 39.3 1612 391-2469
Stage 4 60 8.3 1373.5 195-2466.5
Age category
< 1 year 200 24.6 831 181-2001
1− < 5 years 303 37.3 1673 444-2707
5− < 15 years 310 38.1 2032.5 887-2657
Functional status
Ambulatory 85 11.2 1908 473-2785
Bedridden 12 1.6 401.5 85.5-1916.5
Working 659 87.2 1677 437-2465
clinical stage I of HIV infection, is 1591 days, with an interquartile range (IQR) of
(336.5-2206) days. The children who initiated while in stage II had a much longer
median survival time of 2134 days with an IQR of (609-2867) days. The least median
survival time of 1373.5 days with IQR (195-2466.5) days was observed for children
who initiated ART in the disease clinical stage IV of HIV infection. The children who
initiated ART in a bedridden condition had a median survival time of 401.5 days with
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IQR (85.5-1916.5) days whilst those who started ART in an ambulatory and working
condition had median 1908 with IQR (473-2785) days and 1677 with IQR (437-2465)
days respectively.
The median survival time for infants, that is, children below one year was 831 with
IQR (181-2001) days while those 1− < 5 years and 5− < 15 years was 1673 with IQR
(444-2707) days and 2032.5 with IQR (887-2657) days, respectively.
Figure 4.1 shows the survival estimates for the children who initiated ART between
Figure 4.1: Kaplan-Meier survival estimates curve by clinical stages
2006 and 2010 at Katutura Hospital. The children’s survival probability is estimated
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based on the baseline clinical stage and from Figure 4.1, children who initiate ART in
stage IV has the lowest survival probability curve over the whole period under study.
Children who initiate ART at earlier disease clinical stages have higher survival prob-
abilities. A log-rank statistic of 7.1005 and a p-value of 0.0688 indicates that there is
no statistical difference in the survivor probabilities for the different clinical stages.
However, a low p-value close to 0.05 may be indicative of a possible difference in
survival prospects of children who initiate at different clinical stages.
Figure 4.2 shows that children who initiated on ART at Katutura Hospital with
Figure 4.2: Kaplan-Meier survival estimates curve by absolute CD4 count
a CD4 count below threshold seem to have lower survival probability estimates as
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compared to the other children of the same age who initiate on ART with their CD4
count level above the threshold value. A log-rank value of 1.3581 and a correspond-
ing p-value of 0.2439 indicate that there is no significant difference in the survival
prospects of these groups of children, that is, those that start with their CD4 count
below threshold and those that start when their CD4 is above threshold.
Figure 4.3 shows the 95% Hall-Wellner Bands which are overlapping and thus indi-
Figure 4.3: Kaplan-Meier survival estimates curve by gender
cating that there is no significant difference in the prospects of survival for the male or
female children on treatment. The log-rank statistic of 1.8930 and a corresponding p-
value of 0.1689 confirm that gender has no significant effect on the survival prospects
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for the children on treatment at the hospital. Figure 4.4 shows the survival estimates
Figure 4.4: Kaplan-Meier survival estimates curve by functional status
for the children who initiated ART at Katutura Hospital between 2006 and 2010. The
children’s survival probability is estimated based on the baseline functional status and
from Figure 4.4, the children who initiated ART in a bedridden condition have the
lowest survival probability curve over the whole period under study. Children who
initiate with a working or ambulatory condition have higher survival probabilities. A
log-rank statistic of 5.3293 and a p-value of 0.0696 indicate that there is no statistical
difference in the survivor probabilities for the different functional status, however, a
low p-value close to 0.05 as this may be indicative of a possible difference in survival
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prospects of children who initiate at these different functional status conditions.
Figure 4.5 shows that for the children that were initiated on ART at the hospi-
Figure 4.5: Kaplan-Meier survival estimates curve by age category
tal between 2006 and 2010, the infants had significantly lower survival prospects as
compared to the other age groups. A log-rank value of 31.3799 and a corresponding
p-value of < 0.0001 is indicative of a significant difference in the effect of age group
in affecting the child’s survival chances.
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4.4.2 Proportional hazards model results and analysis
For the proportional hazards model (PHM), all the risk factor variables that had a
p-value less than 20% from the log-rank test were included in the model. According
to this criterion, all the variables except absolute CD4 count were included in the
adjusted Cox proportional hazards model.
From the adjusted Cox regression analysis, Table 4.3, only age category was signifi-
Table 4.3: Cox’s proportional hazards model estimates
Risk factor variable AHR (95% CI) P-Value
Clinical stage
Stage 1 1
Stage 2 1.01 (0.733-1.390) 0.9530
Stage 3 1.142 (0.860-1.515) 0.3596
Stage 4 1.387 (0.888-2.164) 0.1503
Age category
< 1 year 1
1− < 5 years 0.699 (0.534-0.915) 0.0093∗
5− < 15 years 0.546 (0.414-0.721) 0.00001*
Functional status
Ambulatory 1
Bedridden 1.640 (0.741-3.629) 0.2225
Working 0.965 (0.691-1.347) 0.8321
Gender
Female 1
Male 0.939 (0.761-1.158) 0.5548
∗significant at 5% level
cantly associated with the risk of death for the children on ART at Katutura Hospital
for the period under study. Children in the age category 1− < 5 years had an ad-
justed hazard ratio of 0.699 with a 95% CI of (0.534-0.915) showing that this age
group is significantly around 30% less at risk as compared to the infants(< 1 year)
age group. The children who start ART at a much older age group of 5− < 15 years
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were also at low risk of death as compared to the infants. An adjusted hazard ratio
of 0.546 with a 95% CI of (0.414-0.721) was observed for this age group and it shows
that these children are significantly around 45% less at risk when compared to the
infants. All children who started ART in clinical stages II, III and IV were at a higher
risk of death, 1%, 14% and 39% respectively, as compared to those who started in
clinical stage I. However, the data could not highlight any significant difference in
initiating at different clinical stages. Although not significantly different, the children
who initiate on ART with a bedridden condition were around 64% at higher risk as
compared to those who initiate in an ambulatory condition. Those who initiated with
a working functional status were around 4% less at risk of death as compared to those
who initiated with an ambulatory functional status. The child’s gender did not have
a significant effect on the risk of death but being male had less than a 7% protective
effect from death.
4.4.3 Discussion
This study showed that children under the age of one year have a shorter follow-up
(survival) time as compared to the other age groups. Children who started ART in a
bedridden condition had the shortest median survival time amongst all who started
ART in different functional statuses. Most children who were part of this study started
ART when they were already in stage III of the disease, with only a few starting in
the most advanced stage, that is, stage IV. This study also showed that there was a
gradual decrease in the probability of survival for most of the risk factors at different
levels except for WHO stage IV and bedridden conditions where the survival curves
have a sharp decrease. From the Cox proportional hazards model analysis, this study
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found out that the infants who initiated on ART during the period under study were
at high risk of death, that is, being an infant had a significant negative effect on
survival after initiation, as compared to the other age groups of children who were on
treatment. This result highlights the need for close monitoring of infants who start
on ART to make sure that all the complications or reactions that may result due to
the administered regimens may be attended to as quickly as possible. This result is
comparable to a study that was done in a large cohort of HIV positive children in
Zambia (Bolton-Moore et al., 2007). This study could not find any significant effect
for the absolute CD4 count and other clinical variables such as WHO clinical stages
and functional status. A similar study that was done in Ethiopia (Kedir et al., 2014)
found that children who initiated ART with advanced WHO clinical staging, CD4
count below threshold, underweight and low haemoglobin levels were predisposed to
death more than the other children who initiated with different conditions. This study
could not include as many risk factors as these other studies due to the limitations
with the number of variables that the ministry records. However, the results from
the log-rank tests for WHO staging and functional status showed the possibility of a
significant difference in how the different levels of these factors impacted negatively
on the survival prospects of the children under study. This is notwithstanding the
results of the Cox proportional hazards model analysis which did not show these
variables to be significantly affecting the survival prospects of the children.
4.4.4 Conclusions
The findings of this study indicate that the children who start ART in a bedridden
condition, though few, are at a higher risk of death when compared to those who
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start with a working and ambulatory functional status. The same can be said for
those children who start ART at an advanced HIV/AIDS condition, that is, in stage
IV. Targeted close monitoring as well as other interventions should be implemented
for infants that are on ART treatment in order to reduce deaths among this group
of children. Extensive research should also be carried out to identify the reasons why
infants’ survival times are negatively affected by initiating on ART when the treat-
ment is supposed to have a positive effect.
This chapter utilized some descriptive survival analysis techniques to describe the
paediatric HIV/AIDS patient data and then implemented the Cox’s proportional
hazards model to determine the prognostic risk factors for HIV/AIDS patients’ sur-
vival time. The next chapter, that is, Chapter 5, further explores the same dataset
using the Bayesian proportional hazards and the censored quantile regression models.
Chapter 6 also uses the same dataset.
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5.1 Summary
Survival analysis techniques are often used in biostatistics, epidemiological and clin-
ical research to model time until event data. The purpose of this study was to fit
a Bayesian proportional hazards model and a censored quantile regression (CQR)
model to paediatric data and then compare the results in relation to inferences on
the effect of the different prognostic risk factors on anti-retroviral treatment patients’
survival times.
A retrospective cohort study design was conducted for children who initiated anti-
retroviral treatment between 01 January 2006 and 31 December 2010. The sampling
frame constituted 1605 paediatric patients and from these a final sample of 813 chil-
dren was selected.
The results from a Bayesian proportional hazards model indicate that not being an
infant had a positive effect on survival time. Patients initiating treatment in clinical
stage II instead of stage IV had a significant positive effect on survival time.
The results from the censored quantile regression model are more revealing, high-
lighting that initiating in clinical stage II had a significant positive effect on survival
time during the early periods of initiation compared to initiating in clinical stage IV.
The effect reduces towards the 80th quantile, that is, towards the end of the follow-up
period. The results also reveal that the patient’s gender has a significant effect during
the early periods of starting ART but this is not significant at any other point during
treatment.
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The conclusion from this study is that more insights are obtained from using cen-
sored quantile regression models as compared to the Bayesian proportional hazards
models framework. However, it is our belief that in applying both models together, we
can get hazard ratios and insights into how the prognostic risk factors affect survival
time at different time points.
5.2 Introduction
Survival analysis examines and models the time it takes for events to occur. Survival
analysis focuses on the distribution of survival times. Although there are well known
methods for estimating unconditional survival distributions, most insightful survival
modelling techniques examine the relationship between survival and one or more pre-
dictors (Fox, 2008).
Survival analysis techniques are often used in clinical and epidemiological research
to model time until event data (Nakhaee & Law, 2011). The most common approach
that is used to model survival data is through proportional hazards models as intro-
duced by Cox in 1972. This model examines the relative hazard rates for a condition
between covariates or predictors.
In the analysis of regression models for censored survival data, one often wishes to
assess the importance of certain prognostic factors such as age, gender, or race in
predicting survival outcome. This is a general problem which is encountered in most
clinical trials research in cancer and AIDS (Ibrahim, Chen, & MacEachern, 1999).
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In recent years, thanks to modern computational advancements, there have been
several developments in the literature on modelling survival data. Of interest is the
Bayesian perspective that has been introduced and added within the proportional
hazards modelling framework. Censored quantile regression models have also recently
found some traction in survival data analysis. Koenker and Billias (2001), Koenker
and Geling (2001) and Portnoy (2003) all concur that non-linear quantile regression
models have recently emerged and they are an attractive alternative to the popularly
used models such as the proportional hazards and the accelerated failure time models
(Koenker & Bilias, 2001; Koenker & Geling, 2001; Portnoy, 2003).
The proportional hazards model, or Cox regression model, is widely used in the
analysis of time-to-event data to explain the effect of explanatory variables on haz-
ards rates (Stokes, Chen, & Gunes, 2014). The Cox model is fitted by maximising
the partial likelihood function. In the Bayesian approach, the partial likelihood func-
tion is used as the likelihood function in the posterior distribution (Sinha et al., 2003).
On the other hand, censored quantile regression models provide a direct and flexible
approach to modelling survival times without the proportionality hazard constraint
of the proportional hazards model. In clinical studies, quantile regression is helpful
for identifying and distinguishing important prognostic factors for patient subpopula-
tions that are characterised by short or long survival times (Lin & Rodriguez, 2013).
Because lifetime distributions are generally skewed, the quantiles of the lifetimes, for
example the 25th, 50th and 75th percentiles, are more informative than the mean for
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summarising the lifetime distribution (Lin & Rodriguez, 2013).
Quantile regressions as introduced by Koenker and Basset (1978) provide a direct
approach for modelling the quantiles of a response variable as a function of covariates
(Koenker & Bassett Jr, 1978). By modelling these quantiles of a lifetime, insights
can be gained about the dependence of the response distribution on its covariates.
The quantile regression approach has two advantages, that is, the specific parametric
form does not need to be specified for the lifetime distribution and a regression model
can be fitted for each quantile (Lin & Rodriguez, 2013).
In this study paediatric HIV/AIDS survival data is used to implement the Bayesian
proportional hazards model and the censored quantile regression model. Using both
models contributes to additional information being obtained in identifying prognos-
tic risk factors and their effects on prospects of survival for paediatric HIV/AIDS
patients who are taking antiretroviral drugs.
5.2.1 Aim and objectives
The main aim of this study is to show that more insights can be gained on the
dynamics of covariates in relation to patient survival times when a combination of
models are used, in this case, the Bayesian proportional hazards model and then the
censored quantile regression model. The objectives are:
1. Determining the median survival times for patients starting treatment in differ-
ent levels of the risk factors;
2. Fitting a Bayesian Cox proportional hazards model on the paediatric dataset;
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3. Fitting a censored quantile regression model on the same dataset;
4. Comparing and discussing the prognostic inferences obtained from the Bayesian
proportional hazards and the censored quantile regression models.
5.3 Materials and methods
5.3.1 Study design, sample and setting
A retrospective cohort study design was conducted for children who initiated anti-
retroviral treatment (ART) between 01 January 2006 and 31 December 2010. All
children living with HIV/AIDS below the age of 15 and who were on anti-retroviral
(ARV) treatment administered from Katutura Hospital within the period of 2006 -
2010 were included in the sample. All children who did not have complete information
such as missing date of initiation or date of last visit to hospital were dropped from
the sample.
The target population was all the children under 15 years who are on Katutura
Hospital’s records as ART paediatric patients regardless of the period of their ART
initiation. The population constituted 1605 paediatric patients who initiated ART
between 01 January 2006 and 31 December 2010. Of these, a final sample of 813 was
selected.
Missing data from all the variables included in the study were replaced by imputed
values. The multiple imputation (MI) procedures in SAS were implemented. Lo-
gistic regression was used to impute binary and categorical missing values whilst a
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predictive mean matching regression model was used to impute missing values for
continuous variables. These data were obtained from the hospital’s Management In-
formation System database (MIS) with the help of the hospital data clerks.
The study subjects were followed from initiation to December 2014. The setting
for this study was Katutura State Hospital located in Windhoek, the capital city of
Namibia. The hospital has an HIV/AIDS section which deals with all aspects of HIV
case management and care, that is, from enrolment, counselling, initiating, follow-up
and giving out of the drugs to patients during their scheduled visits to the hospital.
5.3.2 Variables of interest
For the purposes of this study and also due to the limitations associated with sec-
ondary data collected from the Ministry of Health and Social Services’ MIS database,
the study covariates were limited to paediatric patients’ gender, baseline World Health
Organisations (WHO) clinical stages of HIV, baseline functional status, baseline age
category and absolute CD4 count. Absolute CD4 count was classified according to
the age of the child and it had two categories; CD4 count below threshold and CD4
count above threshold. CD4 count below threshold was defined as:
• for infants, less than 12 months, CD4 count less than 1500/mm3;
• for age 12− 35 months, CD4 count less than 750/mm3;
• for age 36− 59 months, CD4 count less than 350/mm3;
• for age >= 60 months (5 years) up to 180 months (15 years), CD4 count less
than 200/mm3 (Bong, et al., 2007) .
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The categories for each of the variables were as follows: (also see Table 3.1).
• WHO staging: (1) Stage I (2) Stage II (3) Stage III (4) Stage IV;
• Absolute CD4 count: (1) CD4 below threshold (2) CD4 above threshold;
• Age category: (1) < 1 year (2) 1− < 5 years (3) 5− < 15 years;
• Functional status: (1) Ambulatory (2) Bedridden (3) Working;
• Paediatric gender: (1) Female (2) Male.
5.3.3 Ethical clearance
Ethical clearance was obtained from the Ministry of Health and Social Services and
approval for data collection was granted by the Provincial Medical Doctor (PMD)
stationed at Katutura Hospital. As the study was done using secondary data, indi-
vidual paediatric patients’ consent was not necessary since the database only captured
patient numbers (created for the extracted database to link patient observations over
time) and not names or any other information that may directly be linked to the
patient. The data was also not shared with any third party hence confidentiality was
maintained (See Appendix A.2).
5.3.4 Kaplan-Meier median survival time and log-rank test
The Kaplan-Meier median survival time is based on the Kaplan-Meier survival esti-
mator method. This method is the best for determining median survival times for
follow-up patients as it incorporates the censoring aspect in the computation of the
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estimates. The log-rank tests are used to assess whether there are significant differ-
ences between the survival patterns amongst different levels in which patients initiate
treatment.
5.3.5 Bayesian proportional hazards model
This model is premised on the proportional hazards modelling framework and adds
the Bayesian flavour in estimating the model coefficients. In this approach, the partial
likelihood function 5.3.1 is used as the likelihood function in the posterior distribution
(Sinha et al., 2003). The likelihood is given as:
L(β) =
r∏
j=1
[
exp(β
′
Xj)∑
l∈R(ti) exp(β
′Xl)
]δi
, (5.3.1)
where R(ti) is the risk set at time ti and δi is the indicator variable that takes a value
1 if the outcome of interest is observed at ti. Also the Xj is the vector of covariates
for the individual who dies at the jth ordered death time, tj. The summation in the
denominator of this likelihood function is the sum of the values of exp(β
′
X) over
all the individuals who are at risk at time tj and the β
′s are the coefficients to be
estimated.
5.3.6 Censored quantile regression model
A censored quantile regression model is estimated for the quantiles up to the 80th
percentile. This estimation of coefficient effect variation up to the 80th percentile
gives us a picture of how the different risk factors affect the patients at different
survival times. The model being fit is:
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Q(τ |X = x) = X ′β(τ) + i, (5.3.2)
where Qyi(x) is the τth quantile of follow-up time yi at X (Lin & Rodriguez, 2013).
The quantile function is invariant under a monotone transformation. The following
minimisation equation is used to determine the optimal parameter estimates.
minβ∈RpVn(β) ≡
∑
i∈(i:yi≥xTi β)
τ |yi − xTi β|+
∑
i∈(i:yi<xTi β)
(1− τ)|yi − xTi β|. (5.3.3)
This function represents a linear programming problem which implements the simplex
method to find the optimal β solutions for the objective function (Leng & Tong, 2013).
5.4 Results and analysis
The data were analysed using SAS 9.4 (SAS Institute Inc, 2013) and the results are
shown in the following tables and figures. Table 5.1 shows the patient numbers as well
as the median survival times for children in each category of the risk factor variables
that were considered in this study. The children who started ART in WHO stage IV
of the disease had the lowest median survival time. Low median survival times were
also observed for children that initiated ART in the bedridden health condition as
well as those children who initiated in the age group below one-year. The log-rank
test shows that the survival probabilities were significantly different among children
who initiated ART in different WHO stages (p=0.038) and also different age groups
(p=0.000).
The next sections fit the Bayesian proportional hazards and then the censored quan-
tile regression models. The inferential insights from these models are then discussed.
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Table 5.1: Kaplan-Meier median survival times and log-rank tests
Variable n Median survival time(days) Log-rank p-value
WHO stage
Stage 1 206 2020
Stage 2 220 1792
Stage 3 314 1726
Stage 4 73 1530 p=0.038∗
Absolute CD4 count
CD4 count below threshold 431 2021
CD4 count above threshold 382 2469 p=0.2102
Age category
less than 1 year 200 851.50
1− < 5 years 303 2134
5− < 15 years 310 2465 p=0.000*
Functional status
Ambulatory 96 1712.50
Bedridden 13 447
Working 704 2338 p=0.0502
Gender
Female 412 1977
Male 401 2467 p=0.1508
∗significant at 5% level
5.4.1 Bayesian proportional hazards model results
Further analyses on the effect of the different risk factors on children’s survival times
are in the tables and figures below. Table 5.2 shows the different risk factors that
were considered in this study with the corresponding adjusted hazard ratios (AHR)
linked to each risk factor. From the cohort of children under study, those who initi-
ated ART in the clinical stage I, were at a slightly high risk of death (AHR=1.1237)
on average as compared to those who initiated in the clinical stage II. Those who
initiate ART in stage I have a better chance of survival when compared to those who
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Table 5.2: Mean adjusted hazard ratios (AHR) and quartiles’ specific hazard ratios
Variables
Hazard ratios (95% HPD Interval)
Hazard ratios at quartiles
25% 50% 75%
WHO staging
WHO stage I vs II 1.1237 (0.8151-1.4371) 1.0092 1.1119 1.2265
WHO stage I vs III 0.8453 (0.6389-1.0389) 0.7671 0.8386 0.9163
WHO stage I vs IV 0.8363 (0.5350-1.1858) 0.7119 0.8176 0.9343
WHO stage II vs III 0.7597∗ (0.5720-0.9474) 0.6906 0.7543 0.8219
WHO stage II vs IV 0.7521 (0.4822-1.0672) 0.6424 0.7326 0.8421
WHO stage III vs IV 0.9955 (0.6401-1.3676) 0.8617 0.9721 1.1060
Absolute CD4 count
Below vs above 1.0914 (0.8870-1.3239) 1.0131 1.0860 1.1625
Age category
1− < 5 vs 5-15 yrs 1.2560 (0.9821-1.5538) 1.1523 1.2478 1.3471
1− < 5 vs < 1 yrs 0.6479* (0.4969-0.8099) 0.5915 0.6422 0.6996
5− 15 vs < 1 yrs 0.5198* (0.3909-0.6573) 0.4720 0.5153 0.5616
Functional status
Ambul vs bedridden 0.6317 (0.2353-1.1307) 0.4533 0.5829 0.7498
Ambul vs working 0.9808 (0.6910-1.2780) 0.8768 0.9742 1.0760
Bedridden vs working 1.7547 (0.6956-2.9892) 1.3116 1.6728 2.1014
Paediatric gender
Female vs male 1.1529 (0.9450-1.3915) 1.0739 1.1466 1.2248
∗significant at 5% level
initiate the ART treatment in stages III and IV, with AHR=0.8453 and AHR=0.8363
on average, respectively. Initiating ART in stage II also implied a better chance of
survival when compared to stages III and IV, with AHR=0.7597 and AHR=0.7521
on average, respectively. Those who started ART in stage III were at a better chance
of survival when compared to those who initiated in stage IV with AHR=0.9955 on
average. The effect of clinical stages seem to decrease with time on treatment as
shown by the reducing adjusted hazard ratios (AHR) from 25th to 75th percentiles
on all the different combinations of clinical stages being compared. The risk of death
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among these different children enrolling for ART at different clinical stages was only
significant for those who initiated in stage II compared to those who initiated in
stage III. This indicates that the clinical stage with which the child initiated on ART
had some effect on the child’s chances of survival at any point in the follow-up period.
Initiating ART with a CD4 count below threshold implied a higher risk of death as
compared to those who initiated with an absolute CD4 above threshold (AHR=1.0914).
The risk seems higher in the longer term under treatment when compared to early
periods of initiation. The 95% confidence intervals show that the risk difference is
not significant on average.
The risk of death for the children between 1 and 5 years was higher in this co-
hort as compared to the age group between 5 and 15 (AHR=1.2560). This shows
that on average, all other variables being the same, the [1-5) years age group has a
25.6% higher chance of dying as compared to the [5-15) year age group. The different
quantiles reveals more; the risk of death is much higher for this age group in the later
periods (75th percentile) of taking ART as compared to when they just begin. The
risk profile is not significant since the 95% confidence interval includes 1. The infants
(< 1 year) are at a significantly higher risk of death as compared to both the [1-5)
and the [5-15) year age groups. The risks are much higher during the early initiation
period as compared to the later parts of ARV treatment. Both the 95% confidence
intervals do not include 1 signifying significant risk at these points.
The infants and adolescents who initiated on ART in an ambulatory condition were
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at a lesser risk of death (AHR=0.6317) as compared to those who initiated in a
bedridden health condition. Moreover, the risk of death is high (54.7%) and probably
significant in the early days of initiation, that is, at the 25th percentile of survival
time after initiation (AHR=0.4533) for bedridden children as compared to children
in an ambulatory condition. The risk of death reduces with longer periods spent on
taking ART, that is, at 75th percentile the hazard of death is reduced to 25.02%
compared to that for the first quantile. The variation for the adjusted hazard ratio
of those children who initiate in the ambulatory condition against those in working
condition is small across the three quantiles, that is, the AHR25= 0.8768, AHR50=
0.9742 and AHR75= 1.0760. Bedridden condition puts a high risk of death on chil-
dren as compared to initiating in the working health condition. A higher difference
is noted in the 75th percentile where those children who initiated in a bedridden con-
dition are at a much higher risk of death as compared to those children who initiates
with a working functional condition. The 95% confidence intervals indicate that the
different risk levels are on average not significantly different.
Adjusting for other factors, female children on ART are at a slightly higher risk of
death as compared to their male counterparts. The 95% confidence intervals indicate
that the risk is not significantly different for this cohort of children. The quantiles
hazard ratios however indicate that the risk for female children is only 0.074% higher
compared to male children at the 25th percentile but in the upper survival quantiles,
75%, the risk of dying goes up to 22.48% for female children as compared to male
children of the same age group.
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5.4.2 Censored quantile regression model results
Table 5.3: The estimated parameters for variables at each quantile level
Variable
τs (Quantile levels)
0.05 0.2 0.25 0.4 0.5 0.6 0.75 0.8
WHO stage
Intercept -30 150.3 284 581* 904.3* 1304* 2115* 2186*
WHO stage I 62 156.3 144 9 -16.8 110.4 -275 -262
WHO stage II 120* 325* 320 284 396 500.6* 132 97
WHO stage III 61.5 68.7 -55 -106.5 -79.8 -17.4 -288 -206
WHO stage IV Ref
Absolute CD4 count
Below threshold 2.5 -38 -42 -34 77.5 198.6 125 154**
Above threshold Ref
Age category
1− < 5 yrs 40.5 171.7* 310* 794.5* 860.5* 584.6* 593* 606*
5− < 15 yrs 76.5* 442.7* 636* 1168.5* 1037.8* 759.6* 578* 594*
< 1 yr Ref
Functional status
Ambulatory 19 61.7 116 -31.5 338.8 365.2 191* 91
Bedridden 55 -41.7 -196 -191 -495.5 -857 -1139 -435
Working Ref
Gender
Female -34.5* -182.3∗ -257* -231.5 -198.8 -82.2 -28 -22
Male Ref
∗significant at 5% level
Table 5.3 shows the results from the censored quantile regression model. The quantiles
0.05, 0.2, 0.25, 0.4, 0.5, 0.6, 0.75, and 0.8 were used and censored quantile regressions
were fitted for each of these quantiles. The results in this table indicate that there is
a significant positive effect on survival time of initiating in stage II compared to stage
IV in the early periods of initiating on ART. Initiating with CD4 below threshold has
no significant effect on survival prospects of patients in the early periods of initiation.
However, there is a significant effect in the later periods of being on treatment when
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compared to those who initiates with a CD4 count above threshold. Age category
effect is significant in all quantiles, that is, from start to the end of the follow-up
period. The other interesting result from this table shows that being a female child
has a significant negative effect on survival time in the early periods of initiating on
ART compared to being a male child. Initiating with an absolute CD4 count below
threshold had a significant effect on survival time only in the 80th percentile showing
that compared to starting ART with an absolute CD4 count above threshold; children
have a similar survival path until later on in the treatment process. Functional status
at initiation had no significant effect on survival prospects of the children in this
study. Table 5.4 shows the overall effect test for each of the risk factors at the different
Table 5.4: The overall variable effect at each quantile level (p-values)
Variable
τs (Quantile levels)
0.05 0.2 0.25 0.4 0.5 0.6 0.75 0.8
WHO stage 0.027* 0.026* 0.008* 0.156 0.054 0.000* 0.00* 0.00∗
Absolute CD4 count 0.900 0.554 0.572 0.803 0.587 0.076 0.053 0.008*
Age Category 0.005* 0.000* 0.00* 0.00* 0.00* 0.00* 0.00* 0.00*
Functional Status 0.843 0.760 0.508 0.878 0.305 0.048 0.004* 0.291
Gender 0.045* 0.003* 0.000* 0.067 0.128 0.473 0.657 0.703
∗significant at 5% level
quantiles. A p-value less than 0.05 indicates that the variable effect is significant. The
projected picture in this table is much more interesting. The overall effect of WHO
staging indicates that the clinical stage that a child initiates on ART has a significant
effect in affecting survival time at both ends of the survival time distribution but
it does not have a significant effect in the intermediate survival time periods. The
implication for this is that by using methods that are based on reflecting the average
effect, such patterns may not be noticed yet they are vital in devising policies for
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effective interventions. Also of interest in this table is the effect of gender, which
highlights that gender has a significant effect on influencing survival times in the
early periods of initiating on ART but this has no effect later on in the duration
of taking treatment. Furthermore, age category at initiation had a significant effect
across the whole survival time distribution. Functional status and absolute CD4 count
at initiation had slight effects in the later periods of taking antiretroviral treatment.
The figures below show the treatment effects across all the quantiles and highlight the
results from Tables 5.3 and 5.4. Figure 5.1 shows that initiating in stage II instead
Figure 5.1: The effects of stage I, II and III compared to IV on paediatric patients’
survival
of stage IV has a positive significant effect in the early periods of initiation but
the effect becomes insignificant the longer the time spent on treatment. Initiating
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in stage III as compared to stage IV is not significantly different across the whole
survival distribution. Figure 5.2 shows that the paediatric and adolescent patients
Figure 5.2: The effects of CD4 count below threshold (reference: above threshold), age
category (reference: < 1 year) and gender (reference: male) on paediatric patients’
survival time
who initiated with their absolute CD4 count being below threshold had a smaller
chance of survival when compared to those who initiated with absolute CD4 count
above threshold. The pattern changes however around the 50th quantile and the
effect becomes positive though insignificant. Compared to initiating as an infant
(< 1 year), the other age groups have a positive significant effect on the prospects of
patients’ survival across all quantiles. Being female had a significant negative effect
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on survival time in the early periods of enrolling on treatment. The effect remains
in the negative territory across all quantiles though in the upper quantiles the effect
is no longer significant. Figure 5.3 shows that those patients who initiated in the
Figure 5.3: The effects of functional status (reference: working status) on paediatric
patients’ survival time
bedridden health condition had a smaller chance of survival compared to those who
initiated in the working health status across all the quantiles. Moreover, being in an
ambulatory state has a significant effect on survival time of patients only at a later
point during treatment, that is, from around the 60th quantile for this study.
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5.4.3 Discussion and conclusion
This study highlights that age categories and WHO clinical stages at start of ART
have significantly different effects on patient survival times. This study also demon-
strates that the use of Bayesian proportional hazards models in assessing the effects
of different risk factors on survival of patients on ART can be enlightening due to
the estimation of the hazard ratios at different quartiles. However, the details of how
the different covariates affect the survival of patients across the survival time distri-
bution can be augmented through the use of quantile regression models. This study
shows that variables such as WHO staging had a significant effect on survival time
at both extremes of the survival time distribution, that is, during the early periods
of initiation as well as later towards the end of the follow-up period. The effect was
shown not to be significant in-between. This insight is only possible if the censored
quantile regression models are used in determining the covariate effects on survival
times for patients. The patterns and dynamics of variable effect on survival times
revealed by this modelling strategy are easily missed when the Bayesian proportional
hazards model is used. The other variable which showed the same patterns was the
gender of the patient; being female had a negative effect on the survival time of a
patient during the early periods of initiation only. From the Bayesian proportional
hazards model, the gender of the child, absolute CD4 count and functional status did
not have a significant effect on survival time. In conclusion, the use of these methods,
that is, the censored quantile regression model and the Bayesian proportional hazards
model gives a rich inferential framework on the dynamics of the different prognostic
risk factors’ effects on the survival time of patients on ART.
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This chapter implemented the Bayesian proportional hazards and the censored quan-
tile regression models to identify and assess the different risk factors. The next
chapter, that is, Chapter 6, compares the Cox’s proportional hazards and the cen-
sored quantile regression models’ estimated parameter effects across the survival time
distribution.
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the censored quantile regression
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ards model and the censored quantile regression model: An analysis of the effects
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Statistics: 24 March 2016.
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6.1 Summary
The fitted proportional hazards model quantifies the hazard or risk associated with
each variable on patient survival time. The hazard is estimated for the whole duration
of the survival time (average hazard). The fitted censored quantile regression (CQR)
model reflects the effect of each risk factor on survival time at each quantile. The
censored quantile regression model thus characterizes the effect of risk factors at each
point of the patient survival. The two models reflect relatively similar information
in terms of risk factors in some situations. The censored quantile regression model
gives more insight on the effects of each risk factor at the different quantiles, showing
that the effect is not constant over the duration of patient survival. The CQR model
reveals that a risk factor can significantly affect the survival of patients in the early
periods after initiation or in the later periods of survival on treatment. When survival
time is skewed, as is usually the case, the censored quantile regression models provide
a better picture on the dynamics of how the risk factors affect patient survival at any
point during treatment.
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6.2 Background and purpose of study
In the past two to three decades, quantile regression (QR) has become a more widely
used statistical technique to describe the distribution of a response variable given a
set of covariates (Koenker & Bassett Jr, 1978). This regression approach offers great
flexibility in assessing covariate effects on event times (at quantile levels), thereby
attracting considerable interest in it’s applications in survival analysis and modelling.
In some data types, for example, clinical trials, the marginal distribution of response
is characterized by marked skewness and quantile regression methods are emerging
as popular techniques for exploring the distribution of the event time data. Quantile
regression models the change of quantiles of the conditional distribution of the dura-
tion in response to changes of the covariates (Fitzenberger & Wilke, 2005).
Quantile regression is a statistical method that is used to estimate and conduct in-
ference about conditional quantile functions. Quantile regression methods, as with
classical linear regression which implements the ordinary least squares approach in
estimating models for conditional mean function, offers a mechanism to estimate
models for the conditional median function and a range of other conditional quan-
tile functions (Koenker, 2005). By estimating an entire family of conditional quantile
functions instead of a single conditional mean function, quantile regression techniques
are capable of providing a more complete statistical analysis of the stochastic rela-
tionships among random variables (Koenker, 2005).
Quantile regression techniques are used in a broad range of applications some of
which includes ecology, econometrics and survival analysis. In survival analysis, and
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event history analysis more generally, there is often a desire to focus attention on
particular segments of the conditional distribution, for example survival prospects in
the early periods after starting ART treatment (Koenker, 2005).
While conventional regressions (in this case, the proportional hazards regression
model) estimators show that the survival times or failure times recognise the pres-
ence of some risk factors, quantile regression adds a new dimension to the literature,
suggesting that the effect of the risk factors varies from quantile to quantile of the
survival time distribution. For patients with the higher survival times, the survival
function will barely recognise some risk factors, yet for those with lowest survival
times, their survival function is particularly sensitive to the presence of some risk
factors (Fitzenberger & Wilke, 2005). The implication being that some risk factors
may be significant for shorter survival times whilst some may be significant for the
longest survival times of patients on ART treatment.
Thus, quantile regression techniques can help us obtain a more complete picture of
the underlying relationships among risk factors and survival times. Censored quan-
tile regression addresses the issue of right censoring of the survival times, which is
common in duration analysis.
The current study was carried out in order to compare the use of censored quan-
tile regression and the Cox’s proportional hazards model in assessing the association
among patients’ clinical and demographic variables with their corresponding survival
times. Interestingly, the censored quantile regression methods are nonparametric,
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while the Cox’s proportional hazards are semi-parametric, with the proportionality
assumption being integral.
6.2.1 Purpose of study
The purpose of this study was to compare the effects of covariates on the survival
time distribution using the Cox proportional hazards model and the censored quantile
regression model. The aim being to determine the method that provides a better
characterisation of the covariate effect across the survival time distribution between
these two modelling frameworks.
6.2.2 Objectives
The objectives of the study were to:
• Estimate a proportional hazards model;
• Estimate a censored quantile regression model;
• Make comparisons of the two models in terms of their robustness in inference;
• Determine whether the censored quantile regression method provides a better
characterisation of the effects of the risk factors across the survival time distri-
bution compared to the Cox’s proportional hazards model.
6.3 Significance of the study
This study illustrates the characterisation of the risk factor effects across the chosen
quantile points using both the censored quantile regression and Cox’s proportional
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hazards models. Public health researchers and biostatisticians may find the informa-
tion from this study useful in terms of designing interventions at the right time for
the correct risk factors.
6.4 Materials and methods
6.4.1 Censored quantile regressions
Linear censored quantile regression (CQR) as derived from quantile regression (QR),
introduced by Powell (1984), allow for semi-parametric estimation of quantile re-
gressions for a censored model in a robust way (Powell, 1984). Censored quantile
regression (CQR) is robust against mis-specifications of the error term since only
fairly weak assumptions are required for the error term. Duration data are often
censored. Right censoring occurs when we only observe that a spell has survived
until a certain duration (e.g. when the period of observation ends) but we do not
know exactly when it ends. Left censoring occurs when spells observed in the data
did start before the beginning of the period of observation. Spells who started at the
same time and who finished before the beginning of the period of observation are not
observed. Quantile regression can not be used with left censored data. Left censoring
is also difficult to handle for Cox’s proportional hazards models (PHM) since strong
assumptions have to be invoked to estimate the model (Fitzenberger & Wilke, 2005).
In this analysis, consideration is made on the case of right censoring which both PHM
and CQR are well suited for. The theoretical framework for the CQR models and
how they are estimated are laid out in sections 2.6 and 2.7.
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6.4.2 Cox’s proportional hazards model
Cox’s proportional hazards modelling (PHM) is the basic modelling technique used in
exploring the relationship between the survival experience of a patient and the covari-
ates (risk factors) in survival data analysis. The details of the modelling framework
and the estimation procedures are laid out in section 2.4.
6.4.3 Data and study design
A retrospective cohort study design was conducted for children who initiated anti-
retroviral treatment (ART) between 01 January 2006 and 31 December 2010. A
sample of 813 was used. Missing data from all the variables in the study were replaced
by imputed values. Multiple imputation (MI) methods were used. The setting for this
study was Katutura State Hospital located in Windhoek, the capital city of Namibia.
The variables included are as in Table 3.1, with the exception that the staging variable
was made binary, that is, stages 1 and 2 were combined as well as stages 3 and 4.
This was done also to assess the effect of starting ART in the HIV condition (stages
I and II) compared the the AIDS disease condition (stages III and IV).
6.4.4 Parameter estimation
Cox’s proportional hazards and censored quantile regression models were estimated.
For the censored quantile regression model, the following quantile (τ) values were
used: τ = (0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, and 0.45). The joint model fit of
the proportional hazards and the censored quantile regression models was estimated
on the same quantile values. The joint fit combines the two set of results onto the
same graph for comparative purposes. The estimated effects from both models can
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then be observed on the graph. The R package was used in this study as it provides
the framework for combining the estimated effects from the Cox proportional hazards
model and the censored quantile regression model.
6.5 Results and analysis
This section presents the results and analysis on the comparisons of the two models
using the paediatric dataset. The models were initially estimated individually and
then combined for the comparison using R-package.
6.5.1 Descriptive analysis of the covariates
Table 6.1: Patient distribution
Risk factor Level n(%)
Gender Male 401 (49.32)
Female 412 (50.68)
clinical stages stages I and II 426 (52.4)
stages III and IV 387 (47.6)
Absolute CD4count Below threshold 431 (53.01)
Above threshold 382 (46.99)
Age category < 1yr 200 (24.6)
1− < 5yr 303 (37.27)
5-15yr 310 (38.13)
Functional status Ambulatory 96 (11.81)
Bedridden 13 (1.60)
Working 704 (86.59)
Table 6.1 shows the distribution of the patients in each covariate category. Gender
distribution was even and reflective of the national subgroup population. The number
of children starting treatment in the AIDS condition (clinical stages III and IV) are
slightly lower than those who start in earlier HIV stages, that is, clinical stages I
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and II. The age distribution indicates that the dataset has almost all paediatric and
adolescent age groups well represented. The results in Table 6.1 also reveal that there
were very few children in the bedridden functional status (1.6%), compared to those
who starts treatment in the working functional status (86.59%). Table 6.2 presents
the Cox’s proportional hazard model estimated results from the data.
6.5.2 Cox’s proportional hazards estimates
Table 6.2: Proportional hazards model parameter estimates
Risk factor Level Coef HR=exp(coef) p-value
Gender Male -0.1374 0.8716 0.1643
Female Ref
clinical stages stages III and IV 0.2328 1.2621 0.0241∗
stages I and II Ref
Absolute CD4count Above threshold -0.0791 0.9240 0.4343
Below threshold Ref
Age category 1− < 5yr -0.4596 0.6316 0.00017*
5− < 15yr -0.6870 0.5031 0.0000*
< 1yr Ref
Functional status Bedridden 0.5942 1.8116 0.0872
Working 0.0248 1.0251 0.8711
Ambulatory Ref
∗significant at 5% level
Table 6.2 indicates that there are two significant risk factors, that is, WHO clinical
stage and age category of the child at treatment initiation. Starting treatment in
clinical stage III/IV exposes the children to a high risk of death, 26% risk compared
to initiating in clinical stages I/II. Age category below 1 year (infants) are at a high
risk of death when compared to the other age groups, that is, 5− < 15 years and
1− < 5 years. Censored quantile regression was then used on the same dataset to
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identify the risk factors and the results are in Table 6.3.
6.5.3 Censored quantile regression estimates
Table 6.3: The estimated coefficients for quantile levels
Variable
τs (Quantile levels)
0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45
WHO stage
Intercept 43 129 198 231* 338* 377* 354 393 789
Stage III/IV -34 -79* -151* -178* -274* -332* -359* -316 -434
Stage I/II Ref
CD4count
Above thres 3 17 7 21 25 46 92 136 103
Below thres Ref
Age category
1− < 5 yrs 64* 101* 170* 214* 307* 450* 656* 763* 1070*
5− < 15 yrs 84* 149* 291* 451* 677* 960* 1245* 1578* 2030*
< 1yr Ref
Funct status
Working -31 -77* -109* -115 -143 -86 -45 106 -120
Bedridden -19 -91* -157 -206* -281* -335∗ -349 -278 -796
Ambulatory Ref
Gender
Male 20 27 129* 219* 265* 233* 275 231 325
Female Ref
∗significant at 5% level
Table 6.3 indicates that the different risk factors significantly affect the survival time
of the paediatrics in different ways at different quantile points. Only one variable,
that is, absolute CD4 count (CD4count), does not indicate significant differences in
the effects of starting ART either with an above or below threshold CD count. All the
other variables highlight that at some point in the follow-up, the variables will have
a significant effect on paediatric survival times depending on baseline initiation levels.
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The two models which were estimated as shown in Tables 6.2 and 6.3 were then
combined in R for the graphical assessment of the coefficient effects on the survival
time distribution. To observe the estimated coefficient effects for the Cox’s propor-
tional hazards model, refer to Figure C.1
6.5.4 Comparison of the Cox’s proportional hazards model
and censored quantile regression model
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Figure 6.1: CQR and PHM comparison on risk factor effects
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Figure 6.1 combines and assesses the coefficient effects as estimated through the
Cox proportional hazards model (solid red line) and the censored quantile regres-
sion model (dotted blue line). The figure also shows the 95% bootsrap confidence
intervals for the CQR model coefficient effects. Figure 6.1 indicates that male paedi-
atric patients’ survival time is significantly more than females in the quantiles 0.1 to
around 0.3. Cox proportional hazards model effects highlight that the effect of being
male compared to female is not significantly different from zero (paedgenderMale
plot). The effect of the Cox’s proportional hazards estimates are clearly illustrated in
the zoomed graph, that is, Figure C.1. Starting ART in clinical stages III/IV com-
pared to I/II has a significant negative effect on survival time between quantiles 0.1
and 0.35. The Cox’s proportional hazards model reflects that the effect is negative
overall. The effects are shown not to be significantly different for absolutecd4count,
functionalstatusBedridden and functionalstatusWorking.
6.6 Discussion and conclusion
This study notes that for survival data analysis, these two methods are both essential
and can augment each other. Overall, they reflect the same information about the
variable effects but with different details and insights.
As noted from Figure 6.1, the Cox proportional model indicates an almost constant
effect for the risk variables (see also Figure C.1) for this result, whilst the censored
quantile regression model captures and better characterises the variability in effect
of different risk factor variables on survival time across the distribution. Given that
the Cox proportional hazards are widely used, the question is, can censored quantile
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regression models replace the proportional hazards models? A number of studies such
as Chernozhukov and Hong (2011); Koenker and Geling (2001); Leng et al., (2013);
Wang and Feygenson (2009) among others have demonstrated that censored quantile
regression models can be used successfully in modelling survival (duration) data in
econometrics and other application areas (Chernozhukov & Hong, 2011; Leng & Tong,
2013; Wang & Fygenson, 2009; Koenker & Geling, 2001). Koenker in his work in
2008 suggested that quantile regression for censored survival (duration) data offers a
more flexible alternative to the Cox proportional hazard model for some applications
(Koenker, 2008).
This study shows that censored quantile regression methods can be implemented as
a biostatistics modelling tool that can augment the Cox proportional hazards model
as it gives more insights on the effects of risk factors. The previous chapter, that is,
Chapter 5, implemented the censored quantile regression and the Bayesian propor-
tional hazards models and revealed that the risk factor effects are not constant over
the survival time distribution. The result in this chapter confirms that observation
as can be noted from Figures 6.1 and C.1.
The next chapter, that is, Chapter 7, implements the censored quantile regression
model to an adult MSF Bulawayo dataset for lower survival times (early deaths).
The result will be compared to other studies that were done focusing on similar
survival time bands.
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7.1 Summary
Survival analysis methods are often used to measure the risk of death and identify the
prognostic risk factors for patients’ survival times. Censored quantile regression has
emerged as a powerful survival analysis method as it links the quantiles of patients’
survival times to their demographic and clinical profiles, facilitating the identification
of important prognostic factors. HIV/AIDS has been one of the major epidemic
diseases for the past decades and it is still currently the major cause of deaths in
many African countries. The introduction of antiretroviral treatment (ART) has
been a positive development with regards to improving survival prospects of HIV
patients. The purpose of this study is to implement the censored quantile regression
model and use the results to explore and characterize the effect of demographic factors
at different lower quantiles of the HIV patients survival time. A retrospective cohort
study was used in this study. The target population was all adults in Bulawayo
who started ART in 2004. Medecins Sans Frontieres (MSF) Bulawayo, Zimbabwe,
was purposely approached for the cohort type data suitable for this study and after
receiving the anonymised patient database; the researchers selected the variables of
interest and selected a final sample of 1134 patients based on the inclusion criterion.
Censored quantile regression modelling was used to estimate the quantile estimates
for each demographic and clinical factors at the first five chosen quantile points. These
five quantile points were selected such that they cover the defined shorter survival
time of first year on ART treatment. The results show that all the risk factors have
different effects at different quantile points. In conclusion, the use of censored quantile
regressions revealed some patterns and hence rare insights in the effect of different
risk factors on the patients’ survival time.
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7.2 Introduction
Survival analysis techniques are often used in clinical and epidemiologic research to
model time until event data (Nakhaee & Law, 2011). Survival analysis entails methods
that measure the risk of death or progression of a disease and it provides predictions
that can help clinicians to estimate trends in their patient outcomes. Quantile re-
gression has emerged as a powerful survival analysis method as it directly links the
quantiles of patients’ survival times to their demographic, clinical and serological pro-
files, facilitating the identification of important prognostic factors (Wang, Zhou, & Li,
2013). These methods also allow health planners to predict the HIV/AIDS burden on
the health system and to allocate health services resources appropriately (Nakhaee &
Law, 2011). Health care planning depends on good knowledge of prevalence, which
requires an accurate understanding of survival patterns. Monitoring the length of
survival after diagnosis is, therefore, an important component of the surveillance of
HIV/AIDS. It provides a basis for evaluating individual prognostic factors (Assefa &
Wencheko, 2012). The survival of HIV/AIDS patients depends on a variety of fac-
tors including but not limited to individual patient’s demographic factors, serological
baseline factors and presence of co-morbidities (Bellamy, 2007).
Long-term sustainable treatment is one choice for people living with HIV/AIDS. Not
only can medication slow the progression of the infection, but it can also markedly
suppress the virus, thereby restoring the body’s immune function and permitting
many HIV-infected individuals to lead a normal life and thus increase their survival
time (Grover, Swain, & Ravi, 2014).
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Even though HIV/AIDS drugs have become cheaper and more available because of
a variety of government and private programmes, millions of others still do not have
access to the drugs. The World Health Organisation (WHO) recommends that in
resource-limited settings like Zimbabwe, Namibia and other African countries, HIV
infected adolescents and adults should start antiretroviral treatment (ART) when the
minimum conditions as in the guidelines are met (WHO, 2007).
With proper and timely use of antiretroviral therapy (ARVs) and good health care
support for people living with HIV/AIDS, it has been noted worldwide that the
survival time can be improved (Zachariah et al., 2006). The presence of oppor-
tunistic infections has however impacted negatively on this prospect (Mezzabotta,
2008). Some of the most lethargic opportunistic illnesses which can drastically re-
duce HIV/AIDS patients’ survival time include Tuberculosis (TB), Pneumonia, and
Hepatitis (Mezzabotta, 2008). Of these opportunistic illnesses, TB has been proven
to be the most deadly when it combines with HIV/AIDS (Ngwerume, 2008). How-
ever, ART is known to dramatically improve the survival chances of patients living
with HIV/AIDS (Zachariah et al., 2006).
Since April 2004, Zimbabwe established a National Opportunistic Infections/Antiretroviral
Therapy (OI/ART) programme (Mutasa-Apollo et al., 2014). Early outcomes of pa-
tients initiated on ART in Zimbabwe and other developing countries show that de-
spite ART, between 10 and 15% of individuals die within a median follow-up period
of about 15 months (Harries, Schouten, & Libamba, 2006). Substantial proportions
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(about 70%) of these deaths occur very early after starting ART. In the case of at-
trition, Mutasa-Apollo and co-researchers highlight that the high attrition occurring
among HIV-infected patients in ART care in Sub-Saharan Africa has been widely
documented, with patient retention declining from 86% at 6 months to 77% by 36
months after initiation (Mutasa-Apollo et al., 2014).
Several factors have been attributed to HIV and AIDS mortality after initiation of
ART. In Vietnam, Cuong and co-researchers (Cuong et al., 2012) found that the
predictive baseline factors for AIDS-related death were age > 35 years, clinical stage
III or IV, body mass index (BMI) < 18 kg/m2, CD4 count < 100/l, haemoglobin
level < 100 g/l, and plasma viral load > 100, 000 copies/ml. Tuberculosis (TB) was
the most common cause of death (40%). Zachariah et al., (2006) discovered in their
Malawi study that significant risk factors associated with mortality in the first 3
months and 6 months after ART initiation included WHO clinical stage IV disease,
a CD4 cell count under 50cells/l and increasing grades of malnutrition (Zachariah et
al., 2006). Mutasa-Apollo and co-researchers (Mutasa-Apollo et al., 2014) in their
study in Zimbabwe found that gender (male sex), baseline WHO clinical stage IV
were associated with an increased rate of attrition whilst baseline CD4 cell count
< 50 cells/µl was associated with higher attrition as compared with CD4 cell count
> 200cells/µl. Low weight was also observed as a risk factor for increase in attrition
(Mutasa-Apollo et al., 2014).
Identifying the individual patients initiating in the ART programme who are at risk
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of early deaths in Bulawayo, Zimbabwe would be useful for targeting potential in-
terventions to prevent such deaths. Factors that are associated with early deaths
in patients initiating on ART are not yet well characterised based on exploring the
survival time distribution, because most of the current literature indicates the use
of usual survival models which estimate fixed effects across the whole survival distri-
bution. In this study we hypothesise that the risk factors impact the HIV patients’
survival time differently from quantile to quantile of the survival time distribution.
We thus implement the censored quantile regression (CQR) model for identifying and
characterising the effects of risk factors at different survival time points.
7.3 Aim and objectives
The main purpose of this study is to use a censored quantile regression model in
exploring the survival time distribution of HIV patients who initiated on ART in
2004 through characterising the prognostic risk factor effects at different quantile
points within the first year of starting therapy.
The objectives for this study are to:
• Describe the patients’ characteristics at initiation for the whole period of follow-
up and;
• Characterize the effect of each of the risk factors for the different quantiles of
the survival time distribution in the first year of ART initiation.
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7.4 Materials and methods
7.4.1 A brief introduction to quantile regression models
Quantile regression (QR) is a common way to investigate the possible relationships
between covariates, X, and a response variable, Y. Unlike the mean regression method
that relies only on the central tendency of the data, the quantile regression approach
allows the analyst to estimate the functional dependence between variables for all
portions of the conditional distribution of the response variable. In other words,
quantile regression extends the framework of estimating only the behaviour of the
central part of a cloud of data points onto all parts of the conditional distribution
(El Ghouch & Van Keilegom, 2009).
7.4.2 Quantile regression model parameter estimation
A censored quantile regression (CQR) model was estimated using the following quan-
tiles, or τ values; τ = (0.05, 0.1, 0.15, 0.2, and 0.25). These τ values were chosen
arbitrarily but making sure that they cover the survival time frame for deaths within
the first year of ART initiation. The ordinary least squares method was not used for
the estimation of parameters for this model because the CQR model assumes that the
error term variances are not homogeneous but have the property of heteroscedasticity
(Koenker & Bassett Jr, 1978). Because of this reason, linear programming methods
are used to estimate the parameters of the linear conditional quantile regression model
(Koenker & Hallock, 2001a).
Linear censored quantile regression (CQR) allows for semi-parametric estimation of
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quantile regressions for a censored regression model (Koenker & Bassett Jr, 1978).
CQR is robust against misspecification of the error term since only fairly weak as-
sumptions on the error terms are required. CQR provides consistent estimates of the
quantile regression coefficients βτ , in the presence of fairly general forms of fixed right
censoring.
The Monte Carlo bootstrap resampling method is used to estimate the variances
and standard errors for the estimated parameters (Bilias, Chen, & Ying, 2000). The
SAS Quantlife procedure (SAS Institute Inc, 2013) was used in the estimation of
these parameters. Equation 2.7.12 was used as the objective function for the cen-
sored quantile regression model in this study.
7.4.3 Data source, design and sample
Anonymous secondary data for this research were provided by MSF. MSF’s ART pa-
tient follow-up database was used in capturing the follow-up data at every patient’s
visit and this database was shared with the researcher courtesy of the MSF Monitor-
ing and Evaluation team after the research was endorsed by the Ministry of Health
in Zimbabwe. The data suppliers had no role in the data manipulation, analysis and
decision to submit the manuscript for publication. Furthermore, all individuals who
qualified for ARVs according to WHO guidelines after diagnosis were entered into the
database and at every visit to the hospital the database was updated with the current
patient information, that is: CD4 count; weight and weight gain; and next date for
visiting.
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The database had some patients who started on ART well before 2004 but for in-
clusion into this cohort study sample, a patient had to be alive on 01 January 2004
and receiving ARVs from MSF hospital in Bulawayo or started ART treatment at
the same hospital in 2004 but before 1 January 2005. A retrospective cohort study
design was used and a sample of 1134 HIV patients on ART followed for almost 6
years to July of 2010 from 2004 was considered.
Variables of interest
The data were exported to MS Excel from the MS Access database. The survival
time and a censoring indicator were generated from the data. The censoring variable
was used to identify those patients whose event time, that is, time to death was
observed and also those whose event time was not observed due to loss to follow-up
and the study ending. The risk factors include the baseline variables such as weight
category at first initiation (weight above 60kgs, weight between 45kg and 60kgs, and
weight lower than 45kgs), age category at initiation (age above 50 years, age between
35 years and 50 years, and age lower than 35 years, that is, (15-35 years)), gender
(male and female), profession as at first initiation (unemployed, formally employed,
self-employed, and other), marital status at initiation (single, married, widowed, and
divorced) and WHO stage at initiation (WHO stage: unspecified, stage I, stage II,
stage III, and stage IV). Also see Table 3.2.
Ethics clearance
Ethical clearance was obtained from the Ministry of Health and Child Welfare through
the HIV/TB Research unit, (See Appendix A.1), and approval for data collection
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was granted by the MSF Operational research unit. As the study was done using
secondary data, individual patients’ consent was not necessary since the database
only captured patient identification numbers and not names or any other information
that may directly be linked to the patient. The data was also not shared with any
third party hence confidentiality was maintained.
Analysis
Descriptive statistics for the sample data were done and then a censored quantile
regression model was fitted on the survival times to explore the risk factors’ effect at
different quantiles of patients’ survival time in the early periods after initiation.
7.4.4 Results and analysis
A single data set obtained from MSF was used in the estimation of the censored
quantile regression model (CQR). Some descriptive statistics for the patients’ survival
times were done to ascertain median survival times for different categories of the risk
factor variables for the entire period of follow-up study. The log-rank tests were
also done to assess differences in survival probabilities for patients who initiated in
different levels of the risk factor variables throughout the entire study period. The
CQR model was then estimated for shorter survival times, that is, up to the 0.25
quantile and after its estimation, it was used to do an analysis on the risk factor
effects in different quantiles of the survival time distribution for patients on ART.
The different risk factors which were investigated include gender, profession, marital
status, age category, WHO stage and weight category at initiation. All these factors
are baseline risk factors for HIV/AIDS mortality.
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Descriptive analysis
Table 7.1 shows the sample sizes in each category, median survival times and log rank
test p-values. Table 7.1 shows that the male survival time for the sample is lower
Table 7.1: Median survival times and log-rank tests for risk factor variables for entire
period of follow-up
Variable Level n(%) Median (days) Log-rank
WHO stage Not classified 15(2) 70
Stage 1 146(13) 1386
Stage 2 251(22) 1394
Stage 3 365(32) 1374
Stage 4 357(31) 1309 p=0.000∗
Gender Male 359(32) 1322
Female 775(68) 1372 p=0.0004*
Profession Unemployed 543(48) 1128
Formally employed 352(31) 1706
Self employed 190(17) 1387
Other 45(4) 1121 p=0.0026*
Marital status Single 207(18) 1689
Married 545(48) 1691
Widowed 298(26) 1719
Divorced 84(8) 1104 p=0.0324*
Age category Lower than 35 years 405(36) 1843
Between 35 and 50 years 626(55) 1677
Above 50 years 103(9) 985 p=0.0094*
Weight category Lower than 45kg 107(9) 1148
Between 45 and 60kg 553(49) 1775
Above 60kg 474(42) 1436 p=0.000*
∗significant at 5% level
than that of females. The median survival time for males is 1322 days (3.6 years),
which is less than the overall median survival time for females at 1362.5 days (3.7
years). The table also shows that the median survival time for HIV/AIDS patients
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who initiated onto ART with clinical stage I is 1386 days (3.79 years) whilst that
for those who initiated with clinical stage II is 1394 days (3.82 years). Patients who
started ART with clinical stage III and IV had median survival times of 1374 days
(3.76) and 1309 days (3.58 years) respectively. The median survival time is lower for
HIV/AIDS patients who start ART in clinical stage IV. The patients who started
ART in the age group above 50 years had a lower median survival time compared to
those who initiated in the age groups lower than 50 years. Also patients who initiated
on ART with weight below 45kgs had a lower survival time compared to those who
started with a weight in categories above 45kgs.
With respect to patient profession and marital status at initiation, the formally em-
ployed had higher median survival times overall compared to those who initiated in
any other stated profession. The widowed patients had the largest median survival
time compared to those patients who started ART as single, divorced or married.
Overall, there were significant differences in the survival probabilities or prospects
(as reflected in the log rank tests p-values) for patients who started ART in dif-
ferent WHO clinical stages (p=0.000), age categories (p=0.0094), weight categories
(p=0.000), gender (p=0.0004), profession (p=0.0026) and marital status (p=0.0324).
Defining shorter survival times
To determine the effects of these different prognostic risk factors in early deaths
(shorter survival times) we considered the patients’ first year on treatment. The first
year in this study constitutes the first 365 days (approximately 25th percentile of
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the patients’ survival time in days) after initiation on ART. The identification of
prognostic factors that are associated with these shorter survival times helps in the
designing of care programmes and intervention measures that can then prolong ART
patients’ survival times. Adding the dimension of the characterisation of these prog-
nostic factors across the survival time quantiles will highlight some subtle trends in
the risk factors’ effect at different points of the survival time. Table 7.2 and Figure
7.1 highlight the period under consideration. Table 7.2 shows that 10% of the people
Table 7.2: Percentiles for patient survival time (n=1134)
Percentiles and corresponding survival times
Percentiles (%) 10 20 30 40 50 60 70 80 90
Survival time (days) 42 192 584 1116 1362.5 1448 1558 2075 2196
who initiated on ART at the hospital only managed up to 42 days of survival, 20%
were dead by the 192nd day whilst the median survival time is 1362.5 days. This
indicates that 50% of the people who initiated with HIV/AIDS on ART survived for
approximately four (4) years.
Figure 7.1 shows the distribution of survival times for the 1134 ART patients who
were followed from 2004 to July 2010. The highlighted section of early deaths consti-
tutes the deaths that occurred in the first year of ART initiation. In this study, we
use quantiles 0.05, 0.1, 0.15, 0.2 and 0.25 in the censored quantile model for assessing
the risk factor effects in the early days after ART initiation. Figure 7.1 read together
with Table 7.2 highlights that the one-year period of follow-up for the implementation
of the censored quantile regression model is around the 25th percentile which is the
0.25 quantile point. The next section fits the censored quantile regression model on
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Figure 7.1: The box-plot for survival time (in days) showing the early deaths
the adult MSF Bulawayo dataset up to the 0.25 quantile point.
Assessing the risk factor effects using censored quantile regression model
Table 7.3 below shows the estimates of the effects of different risk factors at differ-
ent quantile levels. This table shows that initiating in clinical stage I had a positive
increasing effect on survival time compared to initiating in stage IV. The effect was sig-
nificantly different from initiating in WHO stage IV at the 0.15 quantile (p=0.0439),
at the 0.2 quantile (p=0.0193) and at the 0.25 quantile (p=0.0085). Starting ART
in WHO stage II also had a positive effect on patient survival time which became
significant at the 0.25 quantile (p=0.0036). Moreover, being formally employed had a
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Table 7.3: CQR parameter estimates for quantiles within first-year of ART treatment
Risk factor variables
Parameter
τs (Quantile levels)
0.05 0.1 0.15 0.2 0.25
WHO stage Intercept 4.3 -22.6 -33.3 37 66.9
Unspecified -0.3 -16.9 -34.5 -186.5 -124.5
WHO stage I -8.7 14 217.3* 302* 355*
WHO stage II -7.7 43.4 91.3 167.7 378.1*
WHO stage III 0.7 14 44.5 87.3 158.4
WHO stage IV Ref - - - -
Profession Employed 11.3 41.6 113.5* 208.5* 215.5*
Other 99.3 340.6 491* 497.5* 736.3*
Self-employed 8.3 34.8 47.8 104.7 54.1
Unemployed Ref - - - -
Age category Above 50 yrs -5.7 -21.7 -87 -140.7* -243.6*
35 to 50 yrs 4.3 12.5 -8.5 -5.7 5.5
Lower than 35 yrs Ref - - - -
Weight category Above 60kg 22.7* 72.2* 158.8 260.2* 363.1*
45 to 60kgs 10.3 39.1 76.5 142.3* 213.3∗
Lower than 45kg Ref - - - -
Gender Female 6 20.2 69.8 82.8 130.5
Male Ref - - - -
Marital status Divorced -9.3 3.4 -21 -118.8 -196.4
Married -4.3 -11.7 -30.5 -149.5* -167.6*
Single -6.7 -12.3 -60.5 -188.5* -262.2*
Widowed Ref - - - -
∗significant at 5% level
positive effect on survival time of patients compared to being unemployed. The effect
became increasingly significant from the 0.15, 0.2 and 0.25 quantile with p-values
0.0318, 0.0026 and 0.0116 respectively. Initiating in the age group above 50 years was
associated with having a negative effect on survival time compared to the age group
below 35 years. The effect was significant at the 0.2 quantile (p=0.0343) and at the
0.25 quantile (p=0.0085).
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Furthermore, starting ART with weight above 60kgs was associated with a signif-
icant positive effect within the first year period in comparison to starting with a
weight below 45kgs. Starting with a weight between 45 and 60kgs was only signifi-
cantly different from initiating with weight below 45kgs towards the end of the first
year period on treatment. In addition, being female on ART was associated with a
positive effect on survival time compared to being male, this effect is however not
significant. The state of being married or single was negatively associated with sur-
vival time compared to those who initiated as widows. The effects of each of these
variables as well as the level of effect across the different quantiles of the survival time
distribution are highlighted in the following figures.
Figure 7.2 below presents the effects of each employment category in comparison
to the state of being unemployed. The formally employed plot suggests that the ef-
fect of being formally employed at initiation of ART on the survival time is positive
and gradually increasing in relation to initiating in the state of being unemployed.
Being self-employed also follows the same pattern but its not significantly different
from being unemployed. Both these effects are not constant but vary from quantile
to quantile.
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Figure 7.2: Estimated parameter effects by quantile level for survival time for profes-
sion (reference: unemployed)
Figure 7.3 below presents the effects of age categories and weight categories in com-
parison to lower than 35 years age group and weight lower than 45kg respectively on
survival time within the first year of antiretroviral treatment. Starting ART with age
above 50 years is associated with a negative effect on survival time and this negative
effect is slightly stronger in the upper tails, that is, towards the end of the first year on
treatment. Initiating in the age group between 35 and 50 years has a constant effect
across all quantiles and the effect is not significantly different from that of initiating
with age group lower than 35 years. Having weight above 60kgs has a significant
positive effect on survival time across all quantiles of the first year treatment period
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Figure 7.3: Estimated parameter effects by quantile level for survival time on age
(reference: below 35 years) and weight (reference: below 45kgs) categories
and the effect becomes stronger towards the end of this period.
Figure 7.4 below presents the effect of initiating in different marital statuses com-
pared to initiating in the state of being widowed. In the lower quantiles, the effect
on patient survival time due to all the different states is relatively constant and not
significantly different from the widowed patients but becomes more negative in the
upper quantiles. Being a female patient on ART had a positive effect on the survival
time compared to being male. In addition, there is a larger positive effect in the
upper quantiles.
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Figure 7.4: Estimated parameter effects by quantile level for survival time on marital
status (reference: Widowed) and gender (reference: Male)
Figure 7.5 below presents the parameter quantile function estimates for WHO stag-
ing. The figure shows that there is a progressively negative effect to the unclassified
group of patients as compared to those who are classified as being in WHO stage IV.
The effect is non-significant initially but it becomes significantly different as survival
time increases towards the 25th percentile. There is also a significant positive effect of
being in WHO stage I as compared to being in WHO stage IV. For the WHO stage II,
there is an initial insignificant positive effect on survival time but the positive effect
becomes larger with increasing survival time and it becomes significant as compared
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Figure 7.5: Estimated parameter effects by quantile level for survival time on WHO
staging (reference: WHO stage IV)
to WHO stage IV effects around the 0.25 quantile. Moreover, there is no significant
effect difference between WHO stage III and WHO stage IV effects at all quantiles.
These results show that regardless of the fact that those patients receive the same
treatment; their survival time will be strongly affected by the baseline weight cat-
egory and WHO clinical stages as well as age group category and profession. The
effects of these factors are not constant over time reflecting on the need to put correct
interventions at different points of patients’ survival on treatment. As noted from
the analysis above, being in a certain category of age, weight, clinical stage, gender
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or marital status is associated with different varying effects on patients’ survival time
at different quantile points within the first year period of treatment.
7.4.5 Discussion
This study determined that being female patient was associated with a positive effect
on survival time, implying that being male was a risk factor for reduced survival time
in the first year of ART treatment. This result relates with a national study obser-
vation from Mutasa-Apollo et al., (2014) who concluded that the male sex is a risk
factor for increasing the attrition rate of this cohort of people. This is also supported
by findings from Koenig et al., (2009) which indicated that males with HIV/AIDS
and on ART have a shorter survival time as compared to their female counterparts
(Koenig et al., 2009).
Mutasa-Apollo et al., (2014) concluded from their national study that baseline weights
of 45 to 60kgs and less than 45kgs had an increased risk of attrition as compared to
patients with weights greater than 60kgs (Mutasa-Apollo et al., 2014). It is inter-
esting to note that from this study, it could also be shown that the weight category
of above 60kgs at initiation, has a positive significant effect on survival time across
the first-year ART treatment survival time distribution, highlighting some additional
critical information that may help in designing interventions. This effect is more pro-
nounced towards the end of the first year of treatment compared to the beginning.
The effect of being in the age group above 50 years at initiation compared to be-
ing below 35 years is significantly negative towards the end of the first year treatment
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phase but not significant in the first few months after starting on treatment.
For early deaths, that is, deaths within the first year of ARV uptake, WHO stage
1 has a positive effect on survival time as compared to WHO stage 4. The effect is
not significant during the early phase after starting on ART, implying that at the
start of treatment, HIV patients in different clinical stages are all equally exposed. A
significant positive effect of being in clinical stages 1 and 2 was evident from approx-
imately the middle of the first year to the end of first year on treatment. This result
is consistent with many other studies (Mutasa-Apollo et al., 2014; Zachariah et al.,
2006) which concluded that patients who start ART in the early stages of HIV have
a greater chance of surviving longer on treatment compared to those who start in the
later stages of HIV.
7.4.6 Conclusion
In conclusion, this study shows that overall the results are similar to those observed
by other scholars. However, when considering early deaths and using quantile regres-
sion models, it was found that the effect of different risk factors on the survival time
during the time period of interest varies from point to point of the survival time.
It can be deduced from this study that additional information can be gained from
using quantile regression models than just concluding with the traditional methods
of analysing survival time of patients on therapy. Therefore these results might help
in finding appropriate measures against different risk factors at different points of
patients’ survival times during their uptake of antiretroviral drugs.
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The next chapter, that is, Chapter 8, summarizes the conclusions from different re-
search objectives that were stipulated in Chapter 1 and the chapter also discusses the
contributions of this study to the literature on survival modelling and analysis.
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General discussion and conclusions
This thesis reflected on the general information about HIV/AIDS care through ART
programmes, the literature on survival analysis and modelling as well as using new
datasets from Zimbabwe and Namibia.
Throughout this thesis, survival analysis and modelling using different methods such
as the Kaplan-Meier survival estimators, log-rank tests, the proportional hazards,
the Bayesian proportional hazards and the censored quantile regression modelling
techniques were presented. The general thrust of this thesis was to highlight the
important insights that can be gained by using the novel censored quantile regression
procedures in survival modelling. The strategy for this exploration was to start off
with the usual basic analysis of survival data and then to fit the proportional hazards
model, identify prognostic risk factors and finally to make inferences. The next step
was to fit a Bayesian proportional hazards model to the same dataset as well as a
censored quantile regression model to identify risk factors. Inferences were then made
in terms of making comparisons to insights that were obtained in applying each of
the modelling procedures. Having noted the important insights that were obtainable
124
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from using censored quantile regressions, this modelling framework was then applied
to another dataset to identify risk factors for shorter survival times. The following
questions based on this thesis’ objectives were responded to as follows:
What are the risk factors for survival of HIV/AIDS patients on an-
tiretroviral treatment using the Cox’s proportional hazards models?
From Chapter 4, only age category was identified as a significant risk factor for
paediatric and adolescents on ART at 5% significant level. All the other variables
were not significant. Being an infant was found to be associated with a significant
negative effect on survival time. A large study in Zambia showed the same outcome
(Bolton-Moore et al., 2007).
What are the risk factors for survival of HIV/AIDS patients on an-
tiretroviral treatment using the Bayesian proportional hazards model and
censored quantile regression models? Can more information be gained
from these models on how risk factors affect patient survival at different
points of the survival time distribution?
The Bayesian proportional hazards and censored quantile regression models were
then implemented on the data. The results from the Bayesian model indicated that
not being an infant had a positive significant effect on survival time compared to
being an infant. Also initiating treatment in clinical stage II was determined to have
a positive significant effect on survival time compared to initiating in clinical stage
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IV. The Bayesian model also revealed that the effect of the different risk factors on
survival time was not fixed across the survival time distribution. The effect was dif-
ferent for the different quartiles. From the censored quantile regression model, it was
determined that initiating in clinical stage II had a significant positive effect on sur-
vival time during the early periods of initiation compared to clinical stage IV. Patient
gender was also shown from the CQR model as having a significant effect during the
early periods of initiation but not significant at any other point during the follow-up
period. Being female was shown to have a significant negative effect on survival time
during these early periods of initiation on treatment. These results highlighted the
insights that can possibly be gleaned from using CQR models in modelling survival
data with intentions to identify risk factors for survival.
What are the risk factors for shorter patient survival times of HIV/AIDS
patients on antiretroviral treatment using the censored quantile regres-
sion models? Are the risk factor effects constant over the period?
Chapter 7 applied the CQR model to determine the risk factors for shorter survival
times in patients on ART treatment. Results showed that the effect of risk factors was
varied at different points of the first year ART treatment survival time distribution.
For this Zimbabwean adult cohort, it was determined that being a female patient
was associated with a positive insignificant effect on survival time within the first
year of ART treatment. Weight category of above 60kg at initiation was shown to
have a positive significant effect on survival time across the first year ART treatment
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survival time distribution compared to weight category of below 45kgs. For the de-
termination of risk factors that are associated with early deaths, the CQR highlights
that some risk factors, such as weight category, are significant towards the end of
the first year ART treatment period. This result is consistent with many other stud-
ies especially relating to which factors were significant in causing deaths to patients
on ART after three or six months (Mutasa-Apollo et al., 2014; Zachariah et al., 2006).
How does the Cox’s proportional hazards model parameter estimate ef-
fects compare to censored quantile regression model estimate effects?
Chapter 6 fitted both the Cox proportional hazards model and the censored quantile
regression model over the survival time distribution to assess and compare the char-
acterisation of the risk factors across the survival time distribution on the paediatric
dataset. The coefficient effects were shown to vary remarkably when the censored
quantile regression model was used as compared to the proportional hazards model.
The Cox’s proportional hazards model indicated that the risk factor effects are almost
constant throughout the survival time distribution. The censored quantile regression
model indicated that a risk factor can be significant at some quantile points in the
patients’ survival time distribution and not significant in others. This result is similar
to what Koenker and Billias (2001) found in their study on reappraisal of the Penn-
sylvania reemployment bonus experiments (Koenker & Bilias, 2001). The implication
of this result is that the general proportional hazards model, despite retaining the
applause from many researchers in the field, fails to capture the dynamic effects of
the risk factors throughout the survival time distribution.
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Findings, conclusions and limitations
The thesis showed that when quantile regression models are used in modelling sur-
vival data, in this case, the HIV/AIDS survival times for patients on ART, the effect
of different risk factors on survival times for patients are shown to vary from one time
point to the other. Whereas the Bayesian proportional hazards model implies to this
dynamism, by estimating the hazard rates at quartiles, also highlighting that the es-
timates are not constant or fixed throughout the survival time distribution, the CQR
models go a step further to highlight significant risk factors at each chosen time point.
As this study has shown, where the proportional hazards model could only indicate
that age category was significant in affecting survival times, the CQR model showed
at what point of the survival time distribution were these risk factors significant. The
CQR model also highlighted the dynamic nature by which the risk factors can affect
survival times through showing that the effect of a risk factor can be significant in
the early periods of initiation and yet after a certain period of continuous treatment,
the risk factor ceases to affect survival time in a significant manner. The advantage
of such an insight is that decision makers can plan based on the pattern of risk factor
effectiveness, thereby helping positively those that are on treatment to aid in their
quest to survive longer.
This thesis clearly shows that additional information is gained from using censored
regression models in modelling survival data. This additional information can be
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invaluable to public health practitioners working in the health care delivery sector
for people living with HIV/AIDS. Koenker et al., (2008) in their work suggest that
censored quantile regression can be a more flexible alternative to the proportional
hazards model as it gives more information about how risk factors impact survival
time (Koenker, 2008).
The contributions of this thesis include a clear illustration of the merits of using CQR
models in survival analysis and modelling when identifying risk factors for patient sur-
vival on treatment. Using these methods enables an exploration of the dynamics of
risk factors throughout the survival time distribution. The thesis managed to show
that the effect of risk factors on patient survival time was not constant throughout
the follow-up period, that is, from initiation to the end of the study period. This
is expected looking at the skewed nature of survival times data. The implication of
this finding is that risk factors should not be treated as a constant risk throughout
a patient’s treatment period but attention should be directed towards limiting the
effects at particular time points. The other significant contribution is that the CQR
methods can be implemented to augment the proportional hazards model in a very
effective and insightful way. These methods can also be used to analyse the effect of
different risk factors at different points in causing early deaths.
From a public health perspective, this thesis posits that these methods and find-
ings can be very useful and effective in designing care intervention programmes for
patients on ART in Namibia and Zimbabwe as well as the region at large.
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Furthermore, this study contributes positively to the literature on survival modelling
by implementing the Bayesian proportional hazards and CQR models in assessing risk
factor effects on ART patient survival times as well as utilizing the CQR models in
determining prognostic risk factors for early deaths among people on ART treatment.
Recent work by Xue and co-researchers (Xue, Xie, & Strickler, 2016) suggest that
the commonly used statistical model for studying time to event data, the Cox pro-
portional hazards model is limited by the assumption of a constant hazard ratio over
time (i.e., proportionality assumption), and the fact that it models the hazard rate
rather than the survival time directly. The censored quantile regression model, de-
fined on the quantiles of time to event, provides an alternative that is more flexible
and interpretable. This thesis has highlighted the strengths of censored quantile re-
gression models in relation to determining prognostic risk factors for patients that
are on ART treatment.
A few challenges and limitations were noted in this study and these include: The
reliance on secondary data meant that the study had to focus on the available col-
lected data rather than the initially anticipated. This was a limitation on assessing
the effect of opportunistic infections for people on ART treatment. Most hospital
records were not complete hence the randomisation process at design of the study
had to be altered in order to find the appropriate records to include in the study.
Variables such as baseline Body Mass Index (BMI), TB status and viral load were
dropped from the study due to heavy missingness.
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Further research could look at implementing the CQR models to prospective cohort
designs as well as in clinical trials where the researcher has some semblance of control
on the measurement of variables as well as monitoring of subjects. The development
of literature on determining hazard rates at each quantile point in the survival time
distribution is another area of research that is still ongoing and needs focus. Develop-
ment of adequate validation methods for the models is also another area that needs
attention.
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B.1 Oral presentations
1. A Survival analysis of HIV positive children on antiretroviral treatment at Katu-
tura hospital, Windhoek, Namibia.
This was an oral presentation during the institutional research week at the
Nambia University of Science and Technology.
Maposa, I. and Blignaut, J.R. (2016). Institutional research week, 21-23
November 2015
Windhoek, Namibia.
2. Bayesian PHM and insights from the CQR model in determining risk factors
for survival in paediatric HIV/AIDS patients on antiretroviral treatment.
This was an oral presentation during the faculty of health and applied sci-
ences research day at the Namibia University of Science and Technology:
Maposa, I. and Blignaut, J.R. (2016). Faculty of health and applied sciences,
13 May 2016
Windhoek, Namibia.
B.2 Conferences and workshops attended and to
be attended
1. Bayesian Biostatistics short course, 4 to 8 November 2013, SACEMA, South
Africa.
2. Clinic on Meaningful Modelling of Epidemiological Data (MMED) International
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Conferences, African Institute of Mathematical Sciences (AIMS) in collabora-
tion with International Clinics on Infectious Disease Dynamics Data (ICI3D)
programme, 02 June to 13 June 2014.
3. Introduction to the Joint Modelling of Longitudinal and Survival Data, with
Applications in R Course, 19 to 21 October 2015, SACEMA, South Africa.
4. Australian Statistical Conference 2016, 5-9 December 2016, Canberra, Aus-
tralia.
Presentation titled: Inferential insights from the censored quantile regression
and bayesian proportional hazards models: a case of paediatric and adolescent
hiv/aids patients on antiretroviral treatment at katutura hospital, windhoek,
namibia.
5. The 58th Annual Conference of the South African Statistical Association, 28
November -01 December 2016, Cape Town, South Africa.
Presentation titled: Bayesian Cox Proportional Hazards model and insights
from the censored quantile regression model for paediatric and adolescent HIV/AIDS
patients on antiretroviral treatment, Windhoek, Namibia.
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Survival analysis methods are often 
used to measure the risk of death and 
identify the prognostic risk factors for 
patients’ survival times. Censored 
quantile regression has emerged as a 
powerful survival analysis method as 
it links the quantiles of patients’ 
survival times to their demographic 
and clinical profiles, facilitating the 
identification of important prognostic 
factors. The purpose of this study is to 
explore and characterize the effect of 
risk factors at different lower quantiles 
of the HIV/AIDS patients’ survival 
time. Data was obtained from 
Medecins Sans Frontieres (MSF) 
Bulawayo, Zimbabwe. Censored 
quantile regression modelling was 
used to estimate the quantile 
estimates for each risk factor at five 
chosen quantile points. The results 
show that all the risk factors have 
varying effects at different quantile 
points. In conclusion, the 
characterization showed that 
censored quantile regression 
modelling gives more insight into how 
the risk factors affect patient’s survival 
prospects at different survival time 
points. 
The effect of baseline weight on patient survival time 
as shown by the quantile estimates highlights that 
more weight at initiation might increase survival 
prospects but with increase in time on ART, the effect 
is reducing and becomes negative. Mutasa-Apollo et 
al concluded that lower baseline weight had  an 
increased risk for attrition as compared to higher 
weight. In our study we have managed to show that 
baseline weight does not have a constant effect 
across the survival time distribution highlighting some 
additional critical information that may help in 
designing  interventions. For deaths within the first 
year of therapy, WHO stage I had a non-significant 
negative impact to survival time as compared to 
WHO stage IV in the first quantile. Surprisingly on a 
general note, median survival time was higher for 
patients in WHO stage I compared to those in WHO 
stage IV implying that in the long term survival 
prospects for patients in WHO stage I maybe better 
than those for patients in WHO stage 4 but in the 
shorter term, given ART guidelines prioritises stage 
III and IV those who start with stages I and II must be 
with critically low CD4 cell count.     
 
Data were provided by MSF Monitoring and 
Evaluation team from their patient follow-up 
database. The study design is a retrospective cohort 
study sample of 2004 HIV/AIDS patients on ART 
followed for 6 years to June of 2010. The total cohort 
sample in the follow-up was 1134 patients. For 
inclusion into this cohort study sample a patient had 
to be alive on 01 January 2004 and receiving ARVs 
from MSF hospital in Bulawayo or started ART 
treatment at the same hospital in 2004 before 1 
January 2005. Excel, STATA version 11 and SAS 
version 9.1 were used in the processing and 
modelling of data. Censored regression (CQR) 
models were fitted in SAS version 9.1.The CQR 
model used is by Bilias, Chen & Ying (2000): 
 
 
 
Where Tau are the quantile points and β are the beta 
coefficients associated with each risk factor. The 
simplex algorithm is used to estimate the optimal β 
coefficients. The Monte Carlo bootstrap resampling 
method was used to estimate the variances and 
standard errors for the β coefficients.  
 
 
 
 
This study shows that overall the results from 
analysing a cohort of HIV/AIDS patients initiating on 
ART are the same as those by different scholars. 
However when we consider early deaths and use 
quantile regression models, we find that the effect of 
different risk factors on the survival time during the 
time period of interest varies from quantile to quantile 
of the survival time. We realise from this study that 
we can gain additional information from using 
quantile regression models than just ending with the 
traditional methods. 
 
 
Survival analysis techniques are often used in clinical 
and epidemiologic research to model time until event 
data (Nakhaee & Law, 2011). Quantile regression 
has emerged as a powerful survival analysis method 
as it directly links the quantiles of patients’ survival 
times to their demographic, clinical and serological 
profiles facilitating the identification of important risk 
factors at different points of survival time (Wang, 
Zhou, & Yi, 2013). With proper and timely use of 
antiretroviral therapy (ART) and good health care 
support for people living with HIV/AIDS, it has been 
widely noted that the survival time can be improved 
(Zachariah, et al, 2006). Some factors that are 
associated with HIV/AIDS deaths especially at early 
stages of ART includes baseline age, weight, 
haemoglobin level, viral load, CD4 cell count, 
opportunistic infections etc. In this study we 
hypothesise that these different risk factors 
impacts the HIV/AIDS patients’ survival times 
differently from quantile to quantile of survival 
time distribution and implements the censored 
quantile regression modelling. The main objective 
of this study is to explore the survival time distribution 
of HIV/AIDS patients who are in the first year of ART 
to identify and characterise the risk factors at 
different quantile points.  
1. Zachariah, R., Fitzgerald, M., Massaquoi, M., Pasulani, O., Arnould, L., 
Makombe, S., et al. (2006). Risk factors for high early mortality in 
patients on antiretroviral treatment in a rural district of Malawi. AIDS , 20 
(18), 2355-2360.. 
2. Assefa, T., & Wencheko, E. (2012). Survival analysis of patients under 
chronic HIV-care and antiretrioviral treatment at Tikur Anbessa 
Specialized hospital, Addis Ababa, Ethiopia. Ethiopean Journal of 
Health Development , 1-2. 
3. Mutasa-Apollo, T., Shiraishi, R. W., Takarinda, K. C., Dzangare, J., 
Mugurungi, O., Murungu, J., et al. (2014, January 29). Patient retention, 
clinical outcomes and attrition-associated factors of HIV-infected 
patients enrolled in Zimbabwe's National Antiretroviral Therapy 
programme, 2000-2010. (M. P. Fox, Ed.) Plosone , 1-9. 
4. Koenker, R., & Hallock, K. F. (2001). Quantile Regression. Journal of 
Economic Perspectives , 15 (4), 144-146. 
5. Wang, J. H., Zhou, J., & Yi, L. (2013). Variable Selection for Censored 
Quantile Regression. Stat Sin , 23 (1), 145-167. 
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A total of 1134 patients were included in the study and 
followed for a maximum of 2447 days. Of these patients 
31.66% were males with a median survival time of 1322 days 
whilst 68.34% were females with a median survival time of 
1372 days. In terms of attrition, 26.46% of the males could 
not be accounted for at the end of the follow-up as compared 
to only 1.29% of the  females. At 42 days 10% (114) of the 
patients had died and at 584 days 20%(226) mode deaths 
had been recorded. At 1363 days half the patients had died.  
The censored quantile regression model wasfitted for 
survival times within the first year of initiation at quantile 
points 0.05, 0.1, 0.15, 0.2 and 0.25. Six (6) risk factors were 
considered in the model, that is, age, baseline weight, sex, 
profession, marital status and WHO staging. Age was not 
significant in affecting patient survival time at all the quantiles 
but showed that it had an increasing positive effect during the 
early stages of ART but effect reduces after the 0.20 quantile 
of survival time. Weight was also not significant but had a 
reducing positive effect until just before the 0.25 quantile and 
shows that after the 0.25 quantile it has a negative effect on 
survival time. Male sex has an insignificant negative effect as 
compared to female sex. All professions except being a 
student had significant negative effect on survival time 
compared to the “other” profession. For marital status, being 
widowed showed a positive significant varying effect on 
survival time as compared to being divorced. WHO stage I 
showed a negative increasing and varying effect as 
compared to WHO stage 4. 
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Figure B.1: Meaningful modelling of epidemiological data (MMED) international
clinic poster, 2-13 June 2014, AIMS, South Africa
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The scourge of HIV/AIDS has 
been around for the past three 
decades but still there is no cure in 
sight hence care and therapy are the 
best way for dealing with the disease. 
Namibia has not been spared from 
this scourge either. The purpose of 
this study is to analyse and determine 
the risk factors that negatively affect 
survival of children younger than 15 
years who are on antiretroviral 
treatment in Windhoek. The study 
also seeks to identify the survival 
prospects of these children given the 
different risk factors. A retrospective 
cohort study design was conducted 
for children who initiated ART at 
Katutura Hospital in Windhoek, 
Namibia. The survival analysis tests 
showed that there are significant 
differences in the survival chances for 
children who initiate in different WHO 
stages and also in different functional 
statuses. Age category was found to 
be a significant risk factor and being 
an infant was associated with a 
significant negative effect on survival 
time. We recommend targeted  
interventions for infants and also 
improved follow-up programs for 
these children. 
Significant risk factors 
We observed from Table 1 that clinical stage, functional status 
and gender of the child were not significant risk factors. Only 
age category was significantly associated with HIV/AIDS 
children mortality.  From Figure 1 we observe that children 
initiating on treatment at different clinical stages have 
significantly different survival prospects at 10% significant 
level but not at 5% significant level. We also observe that 
admission at different functional statuses causes the children 
to have significantly different survival prospects at 10% level 
of significant but not at 5% level. The child’s age category is 
significantly associated with different prospects of survival at 
5% level of significance.  
 
This study showed that there was gradual fall in the 
probability of survival for most of the risk factors at 
different levels except for WHO stage 4 and 
bedridden condition where the survival curves have a 
sharp fall. From the multivariate Cox regression 
analysis, this study found out that the infants who 
initiated on ART during the period under study were 
at high risk of death, that is, being an infant had a 
significant negative effect on survival after initiation, 
as compared to the other age groups of children who 
were on treatment.This result is comparable to a 
study that was done in a large cohort of HIV positive 
children in Zambia (Bolton-Moore et al, 2007). This 
study could not find any significant effect for the 
absolute CD4 count and other clinical variables such 
as WHO clinical stages and functional status. A 
similar study that was done in Ethiopia (Kedir., 
Desta., & Fesseha., 2014) found that children who 
initiated ART with advanced WHO clinical staging, 
CD4 count below threshold, underweight and low 
haemoglobin levels were predisposed to death more 
than the other children who initiated with different 
conditions. This study highlights the need for a 
countrywide survival analysis for paediatrics on ART. 
Descriptive statistics were used to describe the 
distribution of children who are taking ARVs from 
Katutura Hospital in terms of clinical, immunological 
and demographic risk factors. The Kaplan Meier and 
the log rank tests were used to describe survival 
prospects of paediatric patients in different risk 
groups as well identify whether the risk groups are 
significantly different in terms of the survival 
likelihood.  
 
The Cox Proportional Hazards (regression) model 
was used to determine the significant risk factors that 
negatively impact on the survival prospects of the 
children n treatment. The model is given as below: 
 
ℎ1 t = ℎ0 𝑡 𝑒𝑒𝑒 𝛽1𝑋1 + 𝛽2𝑋2 +⋯+ 𝛽𝑝𝑋𝑝  
 
where ℎ1 t  and ℎ0 t  are the hazards for the 
different groups. The 𝛽s are the coefficients for each 
risk factor and are estimated via the Maximum 
Likelihood Methods.  
 
We recommended that the paediatric HIV/AIDS ART 
care policy makers should consider timely 
interventions for infants taking ARVs. We also 
recommend a national study for children on ART so 
that we can identify the similarities in risk exposures 
between children in Namibia and those in other 
countries.  
The number of children (younger than 15 years) 
receiving ART in low- and middle-income countries 
more than doubled from 2009 to 2013, from 355 000 
to 740 000. At the end of 2013, less than one quarter 
(23%, range 21– 25%) of children living with HIV 
were receiving ART in low-and middle-income 
countries compared with more than one third (37%, 
range 35–39%) of adults living with HIV (WHO, 
2014). Paediatric HIV infection is still a leading cause 
of death among children in developing countries with 
mortality rates highest during infancy (Little et al. 
2007). In Namibia, HIV/AIDS is estimated to be 
responsible for 8% of the deaths in children under 
the age of 15 years ranking it among the top three 
causes of deaths in Namibia (MoHSS, 2008).   
Research in other countries has shown that low 
weight-for-height and low CD4% have a significant 
negative effect on survival of children after ART 
initiation. Another large cohort of HIV positive 
children of Zambia found that besides low CD4% and 
low weight-for-height z-score (WHZ), younger age 
and low haemoglobin level were also found to have a 
significant negative effect on survival after initiation of 
ART. This information is not available for the 
Namibian context hence this study seeks to identify 
the risk factors for children in Namibia who are taking 
ARVs 
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 Table 1. Significant  risk factors: Proportional Hazards Model  
Variable AHR (95% CI) P Value 
Clinical Stage   
    Stage I 1  
    Stage II 1.010 (0.733-1.390) 0.9530 
    Stage III 1.142 (0.860-1.515) 0.3596 
    Stage IV 1.387 (0.888-2.164) 0.1503 
Age category   
     <1 year 1  
     1-5 years 0.699 (0.534-0.915) 0.0093* 
     5-14 0.546 (0.414-0.721) <0.0001* 
Functional Status   
    Ambulatory 1  
    Bedridden 1.640 (0.741-3.629) 0.2225 
    Working  0.965 (0.691-1.347) 0.8321 
Gender   
    Female 1  
    Male 0.939 (0.761-1.158) 0.5548 
 
Figure 1: Survival analysis by different risk factors 
Figure B.2: Namibia University of Science and Technology, Institutional research day,
21-23 November 2015, poster: Windhoek, Namibia
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Survival analysis techniques are often 
used in biostatistics and clinical 
research to model time until event 
data. The purpose of this study is to 
fit a Bayesian proportional hazards 
model and a censored quantile 
regression model to paediatric HIV 
data and then compare the results in 
relation to inferences on the effect of 
the different prognostic risk factors on 
patients’ survival times. A 
retrospective cohort study design was  
used. The results of the two methods 
are similar but there is more 
information from the censored 
quantile regression model which 
highlights more information on the 
covariate effects. 
The use of Bayesian proportional hazards 
models in assessing the effects of different 
risk factors on survival of patients on ART 
can be enlightening due to estimation of 
the hazard ratios at different quartiles. The 
details of how the different covariates 
affects the survival of patients across the 
survival time distribution can be 
augmented through the use of quantile 
regression models. Also of note is the 
aspect that the use of these methods 
together, that is, the CQR model and the 
Bayesian proportional hazards model 
gives us a rich inferential framework on 
the dynamics of the different prognostic 
risk factors’ effects on the survival time of 
patients on ART. 
The study design  was a retrospective 
cohort study. Children under the age of 
15 years who are on antiretroviral 
treatment at Katutura hospital, 
Windhoek, Namibia were included in 
the study. The variables of interest at 
baseline include: age category; WHO 
clinical stages; absolute CD4 count; 
gender of child; and functional status. 
Bayesian proportional hazards and 
censored quantile regression models 
were fitted using SAS 9.4 and the 
variable effects on survival time were 
noted.  
 
This study shows that when quantile 
regression models are used, the effect of 
different risk factors on the survival  time 
of patients are shown to vary from quantile 
to quantile. From this study it is clear that 
additional information is gained from using 
censored quantile regression models. 
 
 
Survival analysis focuses on the distribution 
of survival times (Fox 2008). The proportional 
hazards model, or Cox regression model, is 
widely used in the analysis of time-to-event 
data to explain the effect of explanatory 
variables on hazards rates (Stokes, Chen & 
Gunes 2014). The Bayesian approach uses  
the partial likelihood function as the likelihood 
function in the posterior distribution (Sinha, 
Ibrahim & Chen 2003). Censored quantile 
regression (CQR) models provide a direct 
and flexible approach to modelling survival 
times without the proportionality hazard 
constraint of the proportional hazards model. 
In clinical studies, quantile regression is 
helpful for identifying and distinguishing 
important prognostic factors for patient 
subpopulations that are characterised by 
short or long survival times (Lin & Rodriguez 
2013).   
.  
Lin, G., & Rodriguez, R. N. (2013). Using the QUANTLIFE Procedure for 
Survival Analysis. In Proceedings of the SAS Global Forum 2013 
Conference, Cary, NC: SAS Institute Inc. Available at http:/support. sas. 
com/resources/papers/proceedings11/421-2013. pdf. 
Stokes, M., Chen, F., & Gunes, F. (2014). An introduction to Bayesian 
analysis with SAS/STAT® software. In Proceedings of the SAS Global 
Forum 2014 Conference, Cary, NC: SAS Institute Inc. URL 
https://support. sas. com/resources/papers/proceedings14/SAS400-
2014. pdf. 
Ibrahim, J.G., Chen, M. H., MacEachern, S.N. (2000). Bayesian variable 
selection for proportional hazards models. Canad. J. Statist. 37: 701–
717. 
Fox, J. (2008). Cox Proportional Hazards Regression for Survival Data. 
PP 1-18. https://socserv.socsci.mcmaster.ca/jfox/Books/Companion-
1E/appendix-cox-regression.pdf 
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A total of 813 patients were retrospectively 
followed in this study. Table 1 shows only age 
category significantly affected survival times. 
Table 2 shows that WHO stage2 and female 
gender affected survival time early after 
initiation. There is more information on variable 
effect from CQR models. See also Figures 1-3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.3: Namibia University of Science and Technoloy, Faculty research day, 13
May 2016, poster: Windhoek, Namibia
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C.1 SAS code
proc contents data=zimdataset;
run;
proc mi data=zimdataset nimpute=5 seed=135782 out=Imputeddata;
var survivaltime status Gender baselineage clinicalstages baseline_weight ;
class clinicalstages Gender status;
FCS logistic (clinicalstages);
FCS logistic (Gender);
FCS logistic (status);
FCS regpmm (baselineage);
FCS regpmm (baseline_weight);
FCS regpmm (survivaltime);
run;
proc print data=Imputeddata;
run;
proc freq data=Imputeddata;
tables clinicalstages;
by _Imputation_;
run;
ods rtf;
ods graphics on;
proc quantreg data=Imputeddata outest=cqrestimates ci=resampling plots=ALL;
Title ’ Kaplan-Meier-Type Estimator for Censored Quantile Regression and Censor=0’;
class Gender clinicalstages;
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model survivaltime*status(0)= Gender baselineage baseline_weight clinicalstages
/quantile=(0.2 0.4 0.6 0.8) seed=1268;
Gender_Effect: test Gender;
clinicalstages_Effect: test clinicalstages;
baselineage_Effect: test baselineage;
baseline_weight_Effect: test baseline_weight;
ODS OUTPUT PARAMETERESTIMATES=cqrsparms;
by _Imputation_;
run;
ods graphics off;
ods rtf close;
ods rtf;
ods graphics on;
PROC MIANALYZE PARMS(CLASSVAR=FULL)=cqrsparms;
modeleffects Intercept Gender baselineage baseline_weight clinicalstages;
ODS OUTPUT PARAMETERESTIMATES=mian_ cqrsparms;
RUN;
ods graphics off;
ods rtf close;
ods rtf;
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proc phreg data=Imputeddata outest=phmestimates covout;
class Gender clinicalstages;
model survivaltime*status(0)=Gender clinicalstages baselineage baseline_weight;
by _Imputation_;
run;
proc mianalyze data=phmestimates;
modeleffects GenderFemale clinicalstages1__WHO_Stage_1 clinicalstages2__WHO_Stage_2 clinicalstages3__WHO_Stage_3 baselineage baseline_weight;
run;
ods rtf close;
proc print data=phmestimates;
run;
Imputed results code
proc contents data=paedimpute;
run;
proc mi data=paedimpute nimpute=5 seed=135782 out=Imputeddata_paediatrics;
var durationfollowup status paed_gender functional_status agecategory absoluteCD4count WHO_staging;
class WHO_staging paed_gender status functional_status absoluteCD4count agecategory;
FCS logistic (paed_gender);
FCS logistic (functional_status);
FCS logistic (status);
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FCS logistic (absoluteCD4count);
FCS logistic (agecategory);
FCS regpmm (durationfollowup);
run;
proc print data=Imputeddata_paediatrics;
run;
proc freq data=Imputeddata_paediatrics;
tables WHO_staging;
by _Imputation_;
run;
ods rtf;
ods graphics on;
proc phreg data=Imputeddata_paediatrics;
class WHO_staging absoluteCD4count agecategory functional_status paed_gender;
model durationfollowup*status(0)= WHO_staging absoluteCD4count agecategory functional_status paed_gender;
bayes seed=1 diagnostic=all plots=all outpost=out;
hazardratio WHO_staging;
hazardratio absoluteCD4count;
hazardratio agecategory;
hazardratio functional_status;
hazardratio paed_gender;
by _Imputation_;
run;
ods graphics off;
 
 
 
 
155
ods rtf close;
ods rtf;
ods graphics on;
proc quantreg data=Imputeddata_paediatrics outest=crq_paed_estimates ci=resampling plots=ALL; seed=1268;
Title ’ Kaplan-Meier-Type Estimator for Censored Quantile Regression and Censor=0’;
class WHO_staging absoluteCD4count agecategory functional_status paed_gender;
model durationfollowup*status(0)= WHO_staging absoluteCD4count agecategory functional_status paed_gender
/quantile=(.05 .2 .25 .4 .5 .6 .75 .8);
WHO_staging_Effect: test WHO_staging;
absoluteCD4count_Effect: test absoluteCD4count;
agecategory_Effect: test agecategory;
functional_status_Effect: test functional_status;
paed_gender_Effect: test paed_gender;
by _Imputation_;
run;
ods graphics off;
ods rtf close;
C.2 R code
library(survival)
library(quantreg)
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library(foreign)
paeddata<-read.dta("C:\\Users\\imaposa\\Desktop~~
\\IMaposa\\Desktop\\research\\IRPC-poly\\ARV study~~~
\\paediatric HIV stuff\\paediatrics_imputed_R2.dta")
head(paeddata)
fit<-crq(formula=Surv(durationfollowup, status)~
paed_gender+clinicalstage+ absolutecd4count+
agecategory+functional_status, taus=taus1,
data=paeddata, method="Portnoy")
fit
summary(fit, 1:19/20)
plot(summary(fit, 1:19/20))
Sfit<-summary(fit, 1:19/20)
PHit<-coxph(Surv(durationfollowup, status)~paed_gender+
clinicalstage+ absolutecd4count+agecategory+
functional_status, data=paeddata)
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PHit
myplot<-plot.summary.crqs
myplot
fix(myplot)
myplot(Sfit, CoxPHit=PHit)
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C.3 Cox’s proportional hazards effects graph
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Figure C.1: Comparison zoomed PHM parameter effects
 
 
 
 
